Document:

EX-10.1

 Exhibit 10.1 

Execution Copy 
  

	
	 Confidential Materials omitted and filed
separately with the
 Securities and Exchange Commission. Double asterisks denote omissions.

 Companion Diagnostics 

MASTER COLLABORATION AGREEMENT 
  

			
	Between		Tokai Pharmaceuticals, Inc.
			One Broadway, 14th floor
			Cambridge, MA 02142 USA
			hereinafter “Tokai”
		
	and		QIAGEN Manchester Limited
			Skelton House, Lloyd Street North
			Manchester, M15 6SH,
			England
			hereinafter “QIAGEN”

 WHEREAS 
  

	(A)	Tokai is a world-wide operating pharmaceutical company engaged in the research, development, manufacture and commercialization of pharmaceutical products and methods of treatment of patients with pharmaceutical
products. 

  

	(B)	QIAGEN is a global provider of sample and assay technologies including in vitro diagnostics and companion diagnostics in relation to the pharmaceutical industry. 

 

	(C)	The Parties hereby wish to establish a legal framework for their Project-specific collaborations in the field of development and commercialization of in vitro diagnostics and/or companion diagnostics for Tokai
Compounds. 

 NOW, THEREFORE, the Parties agree as follows: 
  

	1.	Definitions 

  

	1.1	Many terms are defined within the provisions of this Agreement. For convenience, the following terms are defined “up-front” for use throughout the Agreement: 

“Activities” shall mean the activities set out in a Schedule to be performed by either Party in connection with a particular
Project. 
 “Affiliate” shall mean any entity which, directly or indirectly, through one or more intermediaries, controls,
is controlled by, or is under common control with a Party, as the case may be. As used in this definition, “control” shall mean the possession of the power to direct or cause the direction of the management and policies of an entity,
whether through the ownership of the outstanding voting securities or by contract or otherwise. 
 “Agreement” shall mean
this Master Collaboration Agreement. 
 “Background Intellectual Property” shall mean Intellectual Property, which is in
existence and Controlled by a Party at the effective date of the respective Schedule. 

 “Business Day” means any day other than a Saturday, Sunday, bank holiday or
public holiday in Boston, Massachusetts USA. 
 “Clinical Trial” shall mean a clinical investigation of a Tokai Product
undertaken or supported by Tokai as part of the development of such pharmaceutical product to obtain information relating to patient outcome and/or selection for therapy with such pharmaceutical product, which clinical investigation includes the use
of the QIAGEN IVD or any prototype of it developed in the respective Project. 
 “Commercialization” and
“Commercialize” shall refer to all activities undertaken relating to the manufacture for commercial sale, new product planning, marketing, distribution and sale of a Tokai Product or QIAGEN IVD, and the process of Commercialization,
respectively. For clarification, this excludes development and regulatory activities. 
 “Confidential Information” shall
mean any confidential or proprietary information of a Party relating to any assay, diagnostic, biomarker, genetic sequence, compound, research project, work in process, future development, scientific, engineering, launch, manufacturing, marketing,
business plan, financial or personnel matter relating to such Party, its present or future products, sales, suppliers, customers, employees, investors or business, including the results arising from this Agreement, whether in oral, written, graphic
or electronic form, that is disclosed by or on behalf of a Party to another Party, or becomes known to a Party as a consequence of performing Activities under this Agreement. Notwithstanding the foregoing, Tokai shall be the disclosing Party with
respect to Clinical Data, Biomarker Data, Tokai Background Intellectual Property and Tokai Foreground Intellectual Property, and QIAGEN shall be the disclosing Party with respect to Analytical Performance Data, QIAGEN Background Intellectual
Property and QIAGEN Foreground Intellectual Property, in each case regardless of the Party that actually discloses such information. 

“Control” or “Controlled” or “Controlling” shall mean, with respect to any item of Intellectual Property,
the possession (other than by operation of this Agreement) of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to assign, or to grant the other Party access or a license or sublicense to, such Intellectual
Property as provided for herein without violating the terms of any agreement or other arrangement with a third party. 
 “Data”
shall mean any and all data, results, conclusions, reports, and other information generated by or for Tokai resulting from the activities performed under a Project. 

“Deliverables” shall mean the Data and/or materials to be provided to Tokai by QIAGEN in connection with a particular Project.

 “Development Project” shall mean a project performed under this Agreement, as agreed between the Parties and set out in a
Schedule. Development Projects may include: (i) biomarker identification and validation, (ii) prototype assay development, (iii) companion diagnostic proof of concept, (iv) in vitro diagnostic development,
(v) enrolment assay 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 2 

 
development, (vi) Clinical Trial support and regulatory consultation, or (vii) support of a Regulatory Submission for a Tokai Product; which project ultimately may result in the
creation and Commercialization of a QIAGEN IVD in Markets under this Agreement. 
 “Effective Date” shall mean the date on
which this Agreement has been signed by both Parties. 
 “EU” shall mean the European Union. 

“Foreground Intellectual Property” shall mean any and all Intellectual Property arising from work performed under a Project
during the Term, whether conceived, discovered, reduced to practice or writing, generated or developed by the employees, consultants, contractors or agents of Tokai and/or its Affiliates and/or by the employees, consultants, contractors or agents of
QIAGEN and/or its Affiliates, solely or jointly. For clarification, Foreground Intellectual Property shall exclude Data. 

“Governmental Authority” shall mean any court, agency authority, department, regulatory body or other instrumentality of any
government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member. 

“Indication” shall mean any disease, syndrome or condition for which a product can be used for treatment or prevention of such
condition, which use is the subject of a separate Regulatory Approval. 
 “Intellectual Property” shall mean all
intellectual property rights, including patent rights (pending or issued), know-how, materials, methods, processes, protocols, inventions or discoveries (whether or not patentable), utility models, registered designs, design rights, copyrights,
copyright registrations, trade secret and other Confidential Information, and similar intellectual property rights. 
 “IVD”
shall mean in vitro diagnostic medical device as defined in the European directive 98/79/EC; for the avoidance of doubt the term IVD includes companion diagnostics for a pharmaceutical product as defined in FDA’s “Guidance for
Industry and Food and Drug Administration Staff—In Vitro Companion Diagnostic Devices” dated August 6, 2014. 
 “Major
Market” shall mean the United States, the EU, Japan, Canada and Australia, unless otherwise agreed in a Project Schedule. 

“Market” shall mean any country of the world in which the applicable Tokai Product is Commercialized. 

“Materials” shall mean the biological samples, compounds, reagents, supplies, products and other goods that Tokai delivers to
QIAGEN, or QIAGEN procures from a third party, for purposes of performing the this Agreement, and all modifications and derivatives of such Materials. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 3 

 “Party” shall mean Tokai or QIAGEN as the context requires and
“Parties” shall mean both Tokai and QIAGEN. 
 “Project” shall mean a Development Project performed under
this Agreement and/or subsequent Commercialization of the respective QIAGEN IVD. 
 “QIAGEN Domain Names” shall mean any
Domain Name identical or similar with the QIAGEN Trademarks under any ccTLD (country code Top Level Domain) and gTLD (generic Top Level Domain) address area. 

“QIAGEN IVD” shall mean an IVD developed by QIAGEN in the course of a Project including its respective development stages.

 “QIAGEN IVD Platform” shall mean a diagnostic instrumentation or device, firmware base software and user interface
software, which may include, for example, the RGQ or QIAsymphony instruments. 
 “QIAGEN Trademarks” shall mean the
trademarks which QIAGEN uses for the Commercialization of the QIAGEN IVD to be used in connection with a Tokai Product. 

“Regulatory Approval” shall mean with respect to a regulatory jurisdiction, any and all approvals, product and/or
establishment licenses, registrations or authorizations of any Governmental Authority, necessary for the commercial manufacture, use, storage, import, export, transport, or Commercialization of a product in such regulatory jurisdiction, including,
where applicable, (i) pricing and reimbursement approval in such regulatory jurisdiction, (ii) pre- and post-approval marketing authorisations (including any prerequisite manufacturing approval or authorisation related thereto),
(iii) labelling approval and (iv) technical, medical and scientific licences. With regard to an IVD, Regulatory Approval would occur upon FDA approval of a Premarket Approval Application or de novo classification or premarket
authorization for the IVD, and similar approvals of Governmental Authorities in other jurisdictions. 
 “Regulatory Submission”
shall mean with respect to a regulatory jurisdiction, any and all submissions, which are necessary to obtain a Regulatory Approval. 

“Schedule” shall mean an attachment executed by the Parties under this Agreement, as described in Section 2, which
details a Project containing a list of Activities, Tokai Compounds, Deliverables, Markets and other terms applicable to a Development Project. 

“Tokai Compound” shall mean a single biological or chemical substance identified in a Schedule that Tokai is developing or
Commercializing for the prevention, treatment, palliation or cure of a disease, syndrome or condition in humans or animals. 
 “Tokai
Domain Names” shall mean any Domain Name identical or similar with the Tokai Trademarks under any ccTLD (country code Top Level Domain) and gTLD (generic Top Level Domain) address area. 

“Tokai Product” shall mean any product containing a Tokai Compound. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 4 

 “Tokai Trademarks” shall mean the trademarks which Tokai uses for the
Commercialization of the Tokai Products with which a QIAGEN IVD will be used. 
 “Trademark” shall mean the Tokai Trademarks
and the QIAGEN Trademarks. 
 “Valid Claim” shall mean a claim in a granted patent for the Tokai Product that: (a) has
not lapsed, expired or been disclaimed and (b) and that has not been revoked, held invalid or otherwise declared unenforceable by a final judgment of a court, tribunal or patent authority of competent jurisdiction from which no appeal has or
can be taken; or a claim in a patent application that has not been: (i) abandoned or disclaimed, or (ii) finally rejected or disallowed by an appropriate administrative agency or court of competent jurisdiction from which no appeal has or
can be taken, or (iii) [**]. 
  

	1.2	Other Definitional And Interpretative Provisions. The words “hereof”, “herein” and “hereunder” and words of like import used in this Agreement shall refer to this Agreement as a
whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. Any capitalized term used in any Schedule but not
otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the words “include”, “includes”
or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import. Except where the context otherwise
requires, the word “or” is used in the inclusive sense connoted by the term “and/or”. This Agreement will be fairly interpreted in accordance with its terms and without any strict construction in favor of or against either Party.

  

	2.	Projects 

  

	2.1	Schedules, Generally. This Agreement shall govern all Projects identified under a Schedule. The period during which Projects may be initiated (hereinafter “Initiation Term”) under this Agreement
is five (5) years as of the Effective Date, or until terminated in accordance with Section 10. QIAGEN shall perform the Activities and provide the Deliverables as set forth in the relevant Schedule and this Agreement in accordance with the
highest prevailing standards of care and skill to be reasonably expected in the field of developing and Commercializing in vitro diagnostics and companion diagnostics, including adherence to all applicable laws, cGLP (with respect to Tokai
Products developed for animals), cGMP, and cGCP practices, and any additional requirements set forth in a Schedule. QIAGEN shall comply with all reasonable and applicable guidelines and instructions that Tokai provides in writing regarding the use,
storage or handling of patient samples or the Tokai Product. QIAGEN shall be responsible for the quality, technical accuracy and completeness of all Deliverables to be generated or provided by it under this Agreement or a Schedule. QIAGEN shall be
responsible for the professional quality, training and supervision of all of its, its Affiliates’ and permitted subcontractors’ personnel who are engaged in the performance of any Activities for a Project under a Schedule. QIAGEN will
perform its foregoing obligations in good faith, using commercially reasonable and diligent efforts to meet the milestones set forth in each Schedule. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 5 

	2.2	Negotiation of Schedules. For each Project conducted under this Agreement, the Parties shall negotiate the specific details and execute a separate written Schedule. Each Schedule shall detail, inter alia,
the scope of Activities, Tokai Compounds, Deliverables, Project time lines, Markets and compensation terms. Throughout the term of Project each Schedule may be subject to scope changes to be agreed in accordance with section 2.3. Once executed by
both Parties, each Schedule and amendment to a Schedule shall be incorporated in its entirety into this Agreement. No Party shall be obliged to enter into any Schedule by virtue of this Agreement. QIAGEN shall not be obligated to perform any
Activities for Tokai until the Parties have executed a Schedule for that Project. 

  

	2.3	Scope Changes. Each time that the Parties agree that the Activities or Deliverables of a Project should be amended or additional Activities or Deliverables should be added to a Project, the Parties shall prepare
a written amendment of the Schedule for such Project. A Party shall not vary from the Activities and Deliverables set out in the original Schedule until the Parties have agreed to do so in writing. 

 

	2.4	Conflicting Provisions. In the event there is a specific conflict between the terms or conditions of this Agreement and the terms or conditions of any Schedule, the terms and conditions of this Agreement shall
govern, unless the Schedule specifically and expressly supersedes this Agreement on a specific matter and then only with respect to the particular Schedule and the matter so specified. 

 

	3.	Materials and Records 

  

	3.1	Materials Delivery. As more specifically provided in each Schedule, Tokai shall without undue delay provide the relevant Materials free of charge to QIAGEN. If QIAGEN considers that Materials provided by Tokai do
not conform to their specifications, then (a) QIAGEN shall provide Tokai a written notice hereof explaining in detail why Materials do not conform and (b) in case the Parties agree on such non-conformance Tokai shall: (i) provide new
or replacement Materials or (ii) if that is not possible, propose and discuss with QIAGEN in good faith an alternative, and amend the Schedule in writing to reflect such alternative. In case the Parties disagree on the question of
non-conformance of Material, the Parties will discuss this matter and agree in good faith on a solution. To the extent Tokai requests that QIAGEN procure Materials directly from the relevant vendor, such procurement may be subject to a handling
charge to be agreed by the Parties in advance. 

  

	3.2	 Use Restrictions. QIAGEN shall handle the Materials in accordance with any applicable documentation, reasonable handling procedures for similar
materials, applicable common scientific standards of care, and Tokai’s written instructions. QIAGEN undertakes to use the Materials only in connection with the Activities described in the applicable Schedule and for no other purpose. QIAGEN
shall use the Materials in accordance with applicable laws. None of the Materials shall be transferred or sold to third parties except to subcontractors approved by Tokai. QIAGEN shall not use the Materials for testing in or

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 6 

	 	
treatment of human subjects except to the extent described in the applicable Schedule. QIAGEN understands and agrees that the Materials are experimental in nature and that Tokai shall not be
liable for any loss, claim, damage or liability which may arise from the use, storage or handling of the Materials by QIAGEN. 

  

	3.3	Audits. During and following the Term, Tokai retains the right to audit or have audited QIAGEN’s records and any other documentation and facilities in relation to development and regulatory activities for a
Project no more than one time per twelve (12) month period during the Term unless there arises a material quality issue that impacts the Project (a “For Cause Audit by Tokai”). QIAGEN agrees to maintain accurate and detailed records
of information pertaining to any particular Project and agrees to grant access to Tokai (or its nominees) or the FDA or any other Governmental Authority in a Market at QIAGEN’s and any other Project related facility upon request. Such audit(s)
will require reasonable prior written notice, no less than 45 days (other than in the case of a For Cause Audit by Tokai and be subject to commercially reasonable security and safety procedures. Should the U.S. Food and Drug Administration
(“FDA”), European Medicines Agency (“EMA”) or any other Governmental Authority in a Market conduct or give notice of intent to conduct any inspection at any investigation site, or take any other action with respect to any
Project, excluding routine audits of the facility, QIAGEN will promptly give Tokai notice thereof, and supply all information and findings pertinent thereto. 

If any audit performed within QIAGEN’s internal program results in any critical and major findings concerning a Project, QIAGEN shall
provide Tokai with a summary of such findings and proposed corrective actions following the completion of such audit. Should the FDA, EMA or any other Governmental Authority conduct or give notice of intent to conduct any inspection at QIAGEN’s
offices or other QIAGEN facility relating to the development or regulatory activities for a Project, excluding routine audits of the facility, QIAGEN will promptly (and no longer than 48 hours) give Tokai notice thereof, and supply all information
and findings which may have an adverse impact on a Tokai Compound, Tokai Product, a QIAGEN IVD or Project(s) to Tokai, but for clarification, excluding any information relating to a third party’s Project or compound. Prior to responding to the
findings of any aforementioned inspection, QIAGEN shall review and discuss such response with Tokai. If the inspection relates solely to a QIAGEN IVD or Project for Tokai, and to the extent permitted by law, Tokai shall be entitled to have a
representative present for such inspection and all interactions with the FDA, EMA or other Governmental Authority with respect thereto. 
  

	3.4	Financial Records. QIAGEN agrees to maintain for a period of seven (7) years after the expiration or termination of this Agreement adequate records of, and copies of all receipts for third party expenses
incurred in connection with the performance of the Activities and allow access to Tokai and its authorized representatives to inspect such records and receipts upon reasonable notice during ordinary business hours and subject to QIAGEN’s
generally applicable security and safety procedures. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 7 

	4.	Interactions with Affiliates and Third Parties 

  

	4.1	Subcontractors. 

  

	4.1.1	Either Party may involve any of its’ Affiliates in the performance of a Project without notice to or consent from the other Party. Any involvement of third party contractors by either Party in performance of a
Development Project under a Schedule requires the prior written consent of the other Party, such consent not to be unreasonably withheld. The foregoing shall not be construed as preventing either Party from using individual consultants.

  

	4.1.2	To the extent that a Party utilizes its’ Affiliates or third party contractors to perform tasks within the scope of a Project, such Party shall ensure all such Affiliates or third party contractors are obligated
to: (i) treat the other Party’s Confidential Information in accordance with the provisions of Section 6, and (ii) assign rights to any Foreground Intellectual Property, Materials and/or Data so that such rights can be
conveyed in accordance with the terms and conditions of Section 7, and (iii) with respect to QIAGEN, that its Affiliates or third party contractors grant audits and inspection rights similar to the right set forth in
Section 3.3 and 3.4; whereas the foregoing shall not limit QIAGEN’s audit and inspection responsibilities. Each Party shall be liable and solely responsible for the acts, performance and compensation of its respective third party
contractors. 

  

	4.2	Contract Laboratories. The Parties may use third party contract laboratories for the performance of certain services such as sample testing pursuant to a Schedule (hereinafter “Contract
Laboratories”). Tokai and QIAGEN shall cooperate reasonably on a case-by-case basis when contracting with such Contract Laboratories. In the absence of an agreement under a Schedule to the contrary, however, Tokai shall be responsible and
authorized to select and contract the Contract Laboratories engaged to assess the clinical utility of a QIAGEN IVD, subject to QIAGEN’s prior consent which may only be withheld in case QIAGEN has reasonable quality concerns with respect to the
performance of such sample testing by such Contract Laboratory. Tokai and QIAGEN shall ensure that the Contract Laboratories are properly certified to do the clinical utility work according to the applicable Schedule for the Project and this
Agreement. QIAGEN shall be solely responsible for the manufacture and supply of a QIAGEN IVD to the Contract Laboratories for clinical utility testing and for sufficient educating and training of the Contract Laboratories personnel as necessary for
conducting the clinical utility testing. QIAGEN also shall be responsible for ensuring that each such Contract Laboratory has or is provided the necessary equipment (including any upgrades) needed to perform any assay developed hereunder, all of
which shall be at Tokai’s expense. 

  

	5.	Payment 

  

	5.1	Fees and Invoices. Tokai shall pay QIAGEN in accordance with the fee/payment provisions set forth in the applicable Schedule. The Parties hereby agree that all Projects shall be performed on the basis of a
milestone-based fee structure, unless agreed otherwise. Payments are made in U.S. Dollars by wire transfer to a bank account specified by QIAGEN in the Schedule. QIAGEN shall issue invoices for payments which are milestone based upon their
completion in accordance with this Agreement and the relevant Schedule. In addition, QIAGEN shall issue separate invoices, at the end of each month, for all reimbursable expenses set forth in Section 5.2 which accrued in the relevant month.
Invoices shall be sent to the following address: 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 8 

 Tokai Pharmaceuticals, Inc. 

One Broadway, 14th floor 

Cambridge, MA 02142 USA 

mentioning John McBride and of the respective Project in the reference line. Tokai shall pay such invoices within 30 days of receipt of the
relevant invoice. 
  

	5.2	Reimbursable Expenses. In addition to the fees payable under Section 5.1, Tokai shall reimburse any direct, out-of-pocket costs reasonably incurred by QIAGEN and labelled as “pass-through costs” in
the Schedule, without any mark-up or surcharge unless otherwise agreed by the Parties in writing in advance. 

  

	5.3	Currency Conversion. 

 IF USD, use: Any costs to be reimbursed by Tokai in accordance
with Section 5.2 which were incurred in a currency other than U.S. Dollars shall be converted into U.S. Dollars using the average of the fixing exchange rates published by Bloomberg under the function “BFIX” for the respective
currency at noon New York time for the applicable calendar quarter If, on any business day, no U.S. Dollar foreign exchange fixing rate is determined by Bloomberg for the relevant currency, the last Bloomberg price of such day (data field
“PX last”) shall be used instead. 
 http://markets.ft.com/ft/markets/researchArchive. asp?report=WORL. 

 

	5.4	Delay: Any payments due under this Agreement shall be due on such date as specified in this Agreement. Any failure by Tokai to make a payment within [**] days after the date when due shall obligate Tokai to pay
interest on the due payment to QIAGEN. The interest period shall commence on the due date (inclusive) and end on the payment date (exclusive). Interest shall be calculated based on the actual number of days in the interest period divided by 360. The
interest rate per annum shall be equal to the [**] rate, fixed [**] prior to the due date and reset to the prevailing [**] rate in monthly intervals thereafter, plus a premium of [**] percent ([**]%). In addition, if Tokai fails to make an
undisputed payment under a Schedule within sixty (60) days after the date due, QIAGEN shall be entitled, in lieu of other remedies hereunder, to suspend its performance under such Schedule until the undisputed payment is made. However, if Tokai
fails to make an undisputed payment under a Schedule within [**] days after the date due, QIAGEN shall be entitled to treat such failure as a material breach by Tokai and terminate this Agreement immediately so long as advance notice pursuant to
Section 10.2.1 had been provided. 

  

	5.5	Taxes. 

  

	5.5.1	All agreed remunerations/fees are considered to be net of value added tax (hereinafter “VAT”). VAT will be due additionally as legally owed to the applicable jurisdiction, payable after receipt of a
proper invoice, which meets all legal requirements according to the applicable VAT-law. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 9 

	5.5.2	To the extent that the goods or services to be provided hereunder are subject to any sales, use, rental, personal property, or any other transaction or indirect taxes under law, payment of said taxes is Tokai’s
responsibility, subject to any applicable exemption entitlement. 

  

	5.5.3	Any Party required to make a payment (hereinafter the “Paying Party”) to the other Party (hereinafter the “Payee”) under this Agreement shall be entitled to deduct and withhold from the
amount payable the withholding tax for which the Paying Party is liable under any provisions of tax law. Any withheld tax shall be treated as having been paid by Paying Party to Payee for all purposes of this Agreement. Paying Party shall timely
forward the tax receipts certifying the payments of withholding tax on behalf of Payee. In case Paying Party cannot deduct the withholding tax due to fulfillment completion of payment obligation by settlement or set-off, Payee will pay the
withholding tax to Paying Party separately. If Paying Party failed to deduct withholding tax but is still required by tax law to pay withholding tax on account of Payee to the tax authorities, Payee shall assist Paying Party with regard to all
procedures required in order to obtain reimbursement by tax authorities or, in case tax authorities will not reimburse withholding tax to Paying Party, Payee will immediately refund the tax amount. 

 

	6.	Confidentiality 

  

	6.1	Use of Confidential Information. Except for the use in connection with the Activities or the performance of this Agreement, including the permitted use in filings and processes for Regulatory Approval, or as
otherwise permitted by either this Agreement or the disclosing Party, each Party shall: (i) not use any Confidential Information of the other Party, (ii) maintain the disclosing Party’s Confidential Information in confidence using the
same degree of care that it uses for its own Confidential Information of like importance, but in no event using less than reasonable care, and (iii) not disclose or transfer any Confidential Information of the disclosing Party (or any materials
which contain such Confidential Information), to any third party; provided, however, that disclosure shall be permitted to the receiving Party’s employees, consultants, agents or subcontractors (and those of its Affiliates) who
reasonably require such Confidential Information for the purposes of this Agreement and who are bound by obligations of non-use and confidentiality with respect to such Confidential Information equal to those set forth in this Section 6.1. Each
Party hereby consents to the disclosure of its Confidential Information by the other Party to any Affiliate of the other Party who reasonably requires such Confidential Information for the purposes of this Agreement, and any such Affiliate shall
treat such Confidential Information in accordance with the terms of this Agreement. Tokai shall also be entitled to disclose QIAGEN’s Confidential Information, only to the extent directly related to the development and commercialization of the
Tokai Product in combination with the QIAGEN IVD and under a binder of confidentiality no less restrictive than the provisions of this Section 6, to: (a) potential or actual commercialization partners for the Tokai Product; and/or
(b) potential or actual sources of financing or acquirers of Tokai. Any disclosures made pursuant to the foregoing Section 6.2(a) or (b) shall not require QIAGEN’s prior written consent unless the party to which Tokai is making
the disclosure is a competitor of QIAGEN as described in QIAGEN’s periodic filings with the Securities Exchange Commission as required by the Securities Exchange Act of 1934. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 10 

	6.2	Non-Confidential Information. The obligations set forth in Section 6.1 shall not apply to any information that the receiving Party can demonstrate by competent proof: (i) was possessed by the receiving
Party or any of its Affiliates prior to disclosure or development under this Agreement, (ii) was developed by the receiving Party or any of its Affiliates independently from disclosure or development under this Agreement, in case of QIAGEN
particularly also without use of the Materials, (iii) is now or becomes later publicly available other than by breach of this Agreement by receiving Party or any of its Affiliates, or (iv) is available to the receiving Party or any of its
Affiliates from a third party that is not legally prohibited from disclosing such information. 

  

	6.3	Compelled Disclosure. Either Party may disclose Confidential Information of the other Party to the extent required to be disclosed by applicable judicial or governmental order, provided, however, that the
receiving Party takes reasonable steps to give the disclosing Party sufficient prior notice in order to contest such order at the request and expense of the disclosing Party, such request made in the disclosing Party’s reasonable discretion,
and, in the event the receiving Party is ultimately required to disclose such Confidential Information, that the receiving Party discloses only such portion of the Confidential Information as is required to be disclosed and seeks, at the disclosing
Party’s request and expense, a protective order to protect the confidentiality of such Confidential Information. 

  

	6.4	Equitable Relief. Each Party agrees that damages may not be an adequate remedy for breach of this Article 6 and that, accordingly, either Party shall be entitled to seek injunctive or other equitable relief to
prevent disclosure of its Confidential Information. 

  

	6.5	Publicity. Promptly following the Effective Date, the Parties shall issue a press release in the form agreed by the Parties. Following such initial press release, no Party hereto may issue any other press release
or other public statement or announcement concerning the terms of this Agreement without the other Party’s prior written consent unless such release includes only those facts that were initially released in accordance with the first sentence of
this Section 6.5. In addition, no Party hereto shall use the name or any trademarks, logos or trade dress of another Party or its Affiliates in any publicity, press release or other form of public announcement or disclosure without the prior
written consent of such other Party. Notwithstanding the foregoing, any Party may disclose the terms or existence of this Agreement if required by law or regulation, including without limitation applicable securities laws and regulations and rules
and regulations of securities exchanges. If the terms or existence of this Agreement are required to be disclosed by law or regulation, such Party will give the other Parties’ prior written notice of the disclosure requirement and a reasonable
opportunity to review and comment on what is intended to be disclosed before disclosure. 

  

	6.6	 Publications. Each Party shall have the right to publish, present or use Foreground Intellectual Property and/or any portion thereof that it
Controls in furtherance of its publication objectives, or for non-confidential discussions with a Third Party (a “Publication”). Tokai will be responsible for and control the timing and scope of any Publication of [**] and Tokai
Foreground Intellectual Property. QIAGEN will be responsible for and control the timing and scope of any Publication of the [**] and QIAGEN Foreground Intellectual Property. Any Publications of the Joint Foreground

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 11 

	 	
Intellectual Property must be agreed and approved by all Parties. Furthermore, Tokai shall not have the right to publish, present or use the [**], QIAGEN Foreground Intellectual Property or any
portion thereof for any Publication without QIAGEN’s prior written consent, and QIAGEN shall not have the right to publish, present or use the [**] or Tokai Foreground Intellectual Property or any portion thereof for any Publication without
Tokai’s prior written consent. Such Publication shall be subject to the provisions of this Agreement relating to confidentiality and non-disclosure. At least [**] days prior to submission for publication, the publishing Party shall submit to
the other Party for review any proposed Publication. The other Party shall review the proposed Publication and provide its comments to the publishing Party within [**] days of receipt. The Parties agree that the non-publishing Party may request the
proposed submission date to be delayed, and the publishing Party agrees to delay, by up to an additional [**] days in order to provide its comments or address concerns regarding the Publication. In addition, upon the other Party’s notice to the
publishing Party that the other Party reasonably believes that one or more patent applications should be filed which relate to Foreground Intellectual Property Controlled by the other Party or Joint Foreground Intellectual Property prior to any
Publication, the publishing Party shall delay the Publication until such patent application(s) have been filed, provided that the other Party will cooperate in expeditiously filing any such patent application(s), and provided further that any such
delay of a Publication will not exceed [**] days from the date of such notice by the other Party to the publishing Party. If the other Party believes that any Publication contains Confidential Information or other proprietary information belonging
to such Party, such Party will notify the publishing Party, which will remove all references to such Confidential Information or proprietary information prior to publication, presentation or use. 

 

	7.	Intellectual Property; Licenses 

  

	7.1	Background Intellectual Property. Each Party acknowledges and agrees that the other Party Controls certain Background Intellectual Property that relates to that Party’s business or operations. Each Party
further acknowledges and agrees that Background Intellectual Property Controlled by the other Party shall, as between the Parties, remain the exclusive property of the other Party. 

Each Party hereby grants to the other Party during the Term a non-exclusive, worldwide, sub-licensable, non-transferable and royalty-free
license under its Background Intellectual Property relevant for a Project solely to the extent such license is necessary for the other Party to carry out its Activities under the respective Project, including subsequent Commercialization by QIAGEN
of the QIAGEN IVD developed in the respective Project for use with the respective Tokai Product and subsequent Commercialization by Tokai of the Tokai Product with the QIAGEN IVD under this Agreement. For the avoidance of doubt, the Parties agree
that the foregoing license does not provide QIAGEN any right to promote or Commercialize a Tokai Product. For the further avoidance of doubt, the Parties agree that the foregoing license does not provide Tokai with any right to promote or
Commercialize a QIAGEN IVD or a laboratory developed test. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 12 

 Notwithstanding the foregoing, if Intellectual Property Controlled by a third party is included
in the Background Intellectual Property of a Party, such Intellectual Property shall only be included into the license grant of this Section 7.1 paragraph 2, if (i) the other Party has committed in writing to comply with the relevant terms
and conditions of the agreement with the third party and (ii) if applicable, the Parties have agreed in writing on the allocation or sharing of any payment obligations towards the third party which may result from the other Party’s use of
the third party’s Intellectual Property. In addition, if the relevant (license) agreement with such third party requires an allocation of Data and Foreground Intellectual Property or licenses deviating from Sections 7.2 and 7.3, (i) the
Controlling Party shall inform the other Party hereof and (ii) upon request of the other Party to include such third party’s Intellectual Property into the license grant under this section 7.1, (iii) the Parties shall negotiate in
good faith provisions deviating from Sections 7.2 and 7.3 and set them forth in writing. For the avoidance of doubt, the foregoing shall also apply to third party Intellectual Property acquired pursuant to Section 7.7. 

 

	7.2	Assignment and License Back of Data. All Data supplied to QIAGEN by Tokai, or generated in any Clinical Trial (including, for example, all patient data), or generated by the Contract Laboratories for or on behalf
of either or both Parties in the course of the Project under this Agreement, or generated by QIAGEN using the Materials shall be owned as follows: 

(a) Tokai shall own all “Clinical Data,” which is defined as [**] derived from any Materials, all as generated by or on behalf
of either Party or both Parties during the course of performing the Activities under a Project or Schedule. Tokai shall be free to use the Clinical Data for any purpose. QIAGEN, as far as it is in the legal position to do so, hereby assigns all of
its right, title and interest in and to such Clinical Data to Tokai, and if it not in a legal position to so assign, QIAGEN hereby grants to Tokai an exclusive, worldwide, irrevocable, perpetual, fully paid-up license to use the Clinical Data for
any purpose. QIAGEN shall promptly provide to Tokai copies of or access to all Clinical Data held by QIAGEN and its Affiliates, and all related supporting documentation, information, results and analyses with respect to QIAGEN’s the Activities
under a Project or Schedule, when and as such Clinical Data become available. 
 (b) Tokai shall own all “Biomarker Data,”
which is defined [**] generated under the Project, all as generated by or on behalf of either Party or both Parties during the course of performing the Activities under a Project or Schedule. Tokai shall be free to use the Biomarker Data for any
purpose. QIAGEN, as far as it is in the legal position to do so, hereby assigns all of its right, title and interest in and to such Biomarker Data to Tokai and if it not in a legal position to so assign, QIAGEN hereby grants to Tokai an exclusive,
world-wide, irrevocable, perpetual, fully paid-up license to use the Biomarker Data for any purpose. 
 (c) QIAGEN shall own all
“Analytical Performance Data,” which is defined as [**], all as generated by or on behalf of either Party or both Parties during the course of performing the activities under the Project and Schedule for the QIAGEN IVD. QIAGEN shall
be free to use the Analytical Performance Data for any purpose. Tokai, as far as it is in the legal position to do so, hereby assigns all of its right, title and interest in and to such Analytical Performance Data to QIAGEN and if it not in a legal
position to so assign, Tokai hereby grants to QIAGEN an exclusive, worldwide, irrevocable, perpetual, fully paid-up license to use the Analytical Performance Data for all purposes. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 13 

 (d) Tokai hereby grants to QIAGEN a non-exclusive, world-wide, royalty-free license and right of
reference to the Clinical Data and Biomarker Data, with the right to sublicense to QIAGEN’s Affiliates or any third party developing, obtaining Regulatory Approval for, manufacturing or selling the QIAGEN IVD under the Development Project on
behalf of QIAGEN, for the sole and limited purpose of, and only to the extent required to carry out its Activities under the Development Project and subsequent Commercialization of the QIAGEN IVD developed within the Development Project for use with
the Tokai Product. QIAGEN shall not use the Clinical Data or Biomarker Data for any purpose other than permitted in this Section 7.2 for as long as such Clinical Data or Biomarker Data constitutes Confidential Information. 

(e) QIAGEN hereby grants Tokai a non-exclusive license and right of reference to the Analytical Performance Data for the sole and limited
purpose of, and only to the extent required to (i) carry out the Activities under the Project and (ii) research, develop and/or obtain Regulatory Approval for, and make, have made, use, sell, offer for sale, import, export and
commercialize Tokai Products. The license shall not be sub-licensable except to any of Tokai’s Affiliates or any third party researching, developing, obtaining Regulatory Approval for, making, having made, using, selling, offering for sale,
importing, exporting or commercializing the Tokai Product, whether alone or in collaboration with Tokai or any of its Affiliates. 
 (f) As
between the Parties, all right, title and interest in and to the Material is and shall remain the property of Tokai. 
  

	7.3	Foreground Intellectual Property. Subject to Section 7.1 paragraph 3, the Parties agree that any Foreground Intellectual Property shall be treated as follows: 

 

	7.3.1	Tokai Foreground Intellectual Property. Tokai shall exclusively own all right, title and interest in and to any Foreground Intellectual Property relating to [**], (iii) improvements to the Tokai Background
Intellectual Property, and (iv) all Foreground Intellectual Property other than QIAGEN Foreground Intellectual Property that is made or conceived solely by employees, consultants, contractors and agents of Tokai and its Affiliates (hereinafter
“Tokai Foreground Intellectual Property”). Tokai hereby grants to QIAGEN a non-exclusive, world-wide, royalty-free license, with the right to sublicense, under the Tokai Foreground Intellectual Property solely to carry out the
Activities under the applicable Project, including subsequent Commercialization of a QIAGEN IVD developed within a Project for use with the applicable Tokai Product. 

 

	7.3.2	 QIAGEN Foreground Intellectual Property. QIAGEN shall exclusively own all right, title and interest in and to any Foreground Intellectual
Property relating to [**], (ii) improvements of QIAGENs Background Intellectual Property concerning the QIAGEN IVD Platform, and (iii) all Foreground Intellectual Property other than Tokai Foreground Intellectual Property that is made or
conceived solely by employees, consultants, contractors and agents of QIAGEN and its Affiliates (hereinafter “QIAGEN Foreground  

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 14 

	 	
Intellectual Property”). QIAGEN hereby grants to Tokai an irrevocable, perpetual, non-exclusive, world-wide, fully paid-up license, with the right to sublicense, under the QIAGEN
Foreground Intellectual Property for carrying out the Activities under the respective Project and to Commercialize the Tokai Product with (x) a QIAGEN IVD or (y) an IVD solely (1) in the event of a termination of this Agreement by
Tokai pursuant to Section 10.2 or (2) in any Market for which QIAGEN declines to seek Regulatory Approval for the QIAGEN IVD. 

  

	7.3.3	Joint Foreground Intellectual Property. The Parties shall jointly own an equal, undivided interest in and to any Foreground Intellectual Property, other than Tokai Foreground Intellectual Property and QIAGEN
Foreground Intellectual Property, that is made or conceived jointly by employees, consultants, contractors and agents of Tokai and its Affiliates and by employees, consultants, contractors and agents of QIAGEN and its Affiliates (hereinafter
“Joint Foreground Intellectual Property”). In the event that a jurisdiction requires consent of co-owners for one co-owner to grant license rights under or otherwise exploit Joint Foreground Intellectual Property, each Party hereby
grants to the other Party and its Affiliates a sublicensable right and license to exploit such Joint Foreground Intellectual Property without a requirement of accounting other than as set forth in this Agreement. 

 

	7.3.4	Protection of Foreground Intellectual Property. The Parties will inform each other about any Foreground Intellectual Property without unreasonable delay after it has been conceived by their employees, agents or
consultants. The Parties shall take all legally required steps to ensure and effect the allocation of the Foreground Intellectual Property as provided in Sections 7.3.1 through 7.3.3 at the sole expense of the Party owning the Foreground
Intellectual Property according to Sections 7.3.1 through 7.3.3 and, the other Party shall provide reasonable assistance and all necessary documentation and declarations to perfect the rights in the Foreground Intellectual Property (e.g.,
documents for proof of chain of title). Each Party will provide the other Party with thirty (30) days prior notice before pursuing patent protection on the Foreground Intellectual Property allocated to it according to Sections 7.3.1 through
7.3.3. Tokai shall be responsible for the preparation, filing, prosecution and maintenance of the Tokai Foreground Intellectual Property and Joint Foreground Intellectual Property. QIAGEN shall be responsible for the preparation, filing, prosecution
and maintenance of the QIAGEN Foreground Intellectual Property. 

  

	7.4	Defence and Enforcement. Each Party shall promptly notify the other Party in the event it becomes aware of any third party activities that may constitute infringement of any Intellectual Property that is subject
to this Agreement, and/or of any third party claims or allegations contesting the validity and/or enforceability of any such Intellectual Property. QIAGEN shall have the right, but no obligation, to control, enforce, and defend worldwide, at its own
expense, Intellectual Property rights in QIAGEN Background Intellectual Property and QIAGEN Foreground Intellectual Property. Tokai shall have the right, but no obligation, to control, enforce, and defend worldwide, at its own expense, Intellectual
Property rights in Tokai Background Intellectual Property and Tokai Foreground Intellectual Property. With respect to any Joint Foreground Intellectual Property, the Parties will promptly thereafter consult and cooperate to determine a course of
action, which may include, without limitation, the commencement of legal action by any or all of the Parties to terminate or otherwise address such infringement, misappropriation or misuse, and/or to defend the Joint Foreground Intellectual
Property. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 15 

	7.5	Patent Term Restoration. The Parties agree to cooperate and to take reasonable actions to maximize the protections available under the safe harbor provisions of 35 U.S.C. 103(c) for United States patents and
patent applications. The Parties shall cooperate with each other, including without limitation to provide necessary information and assistance as another Party may reasonably request, in obtaining patent term restoration or supplemental protection
certificates or their equivalents in any country in the Territory where applicable to the Foreground Intellectual Property. 

  

	7.6	Trademarks. 

  

	7.6.1	Tokai shall have the sole right to select, register and maintain the Tokai Trademarks at its own expense, and shall own and retain all right, title and interest in and to such Tokai Trademarks, and all goodwill
associated with or attached to the Tokai Trademarks arising out of the use thereof by Tokai, its Affiliates and third party licensees shall inure to the benefit of Tokai. Only Tokai will be authorized to initiate at its own discretion legal
proceedings against any infringement or threatened infringement of the Tokai Trademarks. Tokai shall be responsible for the registration, hosting, maintenance and defence of the Tokai Domain Names. For the avoidance of doubts, Tokai is allowed to
register such Domain Names in its own name, to host on its servers, maintain and defend these Domain Names and use them for websites. 

  

	7.6.2	QIAGEN shall have the sole right to select, register and maintain the QIAGEN Trademarks at its own expense, and shall own and retain all right, title and interest in and to such QIAGEN Trademarks, and all goodwill
associated with or attached to the QIAGEN Trademarks arising out of the use thereof by QIAGEN, its Affiliates and third party licensees shall inure to the benefit of QIAGEN. Only QIAGEN will be authorized to initiate at its own discretion legal
proceedings against any infringement or threatened infringement of the QIAGEN Trademarks. QIAGEN shall be responsible for the registration, hosting, maintenance and defence of the QIAGEN Domain Names. For the avoidance of doubt, QIAGEN is allowed to
register such Domain Names in its own name, to host on its servers, maintain and defend these Domain Names and use them for websites. 

  

	7.6.3	The Parties recognize the exclusive ownership of each other Party’s Trademarks, logotype or trade dress furnished by such Party for use in connection with the marketing, sale or distribution of the Product as
defined in this Agreement. The Parties shall not, either while this Agreement is in effect, or at any time thereafter, register, use or challenge or assist others to challenge the other Party’s Trademarks, logotype and trade dress furnished by
each Party for use in connection with the marketing of the products as defined in this Agreement or attempt to obtain any right in or to any such name, logotype, trademarks or trade dress confusingly similar for the marketing of the products as
defined in this Agreement or any other goods and products, notwithstanding that such goods or products have a different use or are dissimilar to the products as defined in this Agreement. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 16 

	7.6.4	Each Party hereby grants to the other Party a non-exclusive, world-wide, sub-licensable, non-transferable and royalty-free license under its Trademarks relevant for a Project to the extent such license is necessary for
the other Party to carry out its Activities under the respective Project, including subsequent Commercialization by QIAGEN in accordance with Section 8 of this Agreement of the QIAGEN IVD developed in the respective Project for use with the
respective Tokai Product and subsequent Commercialization by Tokai of the Tokai Product with the QIAGEN IVD under this Agreement. 

  

	7.7	Third Party Intellectual Property Licenses 

  

	7.7.1	Licenses relevant for the Tokai Product 

 For the avoidance of doubt, Tokai shall be
solely responsible, at its own discretion and expense, for obtaining and maintaining any licenses or other rights to access or use any other third party Intellectual Property that is necessary for the development, manufacture, use or
Commercialization of any Tokai Product, including but not limited to treatment decisions derived from a diagnostic result and/or patient selection and/or stratification and/or biomarkers. QIAGEN agrees to cooperate reasonably with Tokai to assist
Tokai’s acquisition of any licenses that it is obligated to obtain pursuant to Section 7.6.1; provided, however, that such cooperation shall not include the undertaking of any financial obligations such as the payment of
royalties, milestones or the like, unless otherwise agreed between the Parties. 
  

	7.7.2	Licenses relevant for the QIAGEN IVD. 

 QIAGEN shall be solely responsible, at its own
discretion and expense, for obtaining and maintaining any licenses or other rights to access or use any third party Intellectual Property related to: 

(i)    [**] 
 (ii)
  [**], 
 (iii)  [**], 

to the extent necessary for the development, manufacture, use or Commercialization by QIAGEN of such QIAGEN IVD pursuant to this Agreement.

  

	8.	Commercialization of the QIAGEN IVD as Companion Diagnostic; Supply of IVDs 

  

	8.1	General Principles. The Parties agree that the ultimate goal of each Project conducted under this Agreement is the Commercialization of a QIAGEN IVD used in connection with the Tokai Product. The determination of
whether and to which extent and in which countries or territories the Tokai Product shall be Commercialized shall be within Tokai’s sole discretion. To the extent Tokai Commercializes a Tokai Product in certain countries or territories, QIAGEN
shall Commercialize the corresponding QIAGEN IVD in each Major Market, and may Commercialize such QIAGEN IVD in such other markets included in the Project Schedule. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 17 

	8.2	QIAGEN’s Commercialization Obligations. QIAGEN shall be responsible to Commercialize or have Commercialized by a subcontractor the QIAGEN IVD according to the terms and conditions herein. Within the
timeframe set forth in the relevant Schedule, QIAGEN shall prepare and the Parties (acting through the JSC) shall agree upon a commercialization plan (“Commercialization Plan”) for launch, marketing and sale of the QIAGEN IVD in the
Markets in accordance with its customary commercial practices. For clarity, any activities that are: (a) outside the scope of QIAGEN’s customary commercial practices; or (b) that are tailored to, or necessarily connected to the same
activities for, the Tokai Product, the Parties shall mutually agree on the plan and funding for such activities in the Commercialization Plan. Each Commercialization Plan shall, among other things, [**]. Without limiting the foregoing, QIAGEN shall
use commercially reasonable and diligent efforts to: (a) ensure the availability of the QIAGEN IVD for purchase in the Markets for use in connection with the initiation and ongoing treatment of patients with the Tokai Product and
(b) collaborate with Tokai to seek any necessary reimbursement approvals for the QIAGEN IVD from Governmental Authorities and other third party payors in each of the Major Markets. In addition, while QIAGEN shall be entitled to establish the
price to be charged for the QIAGEN IVD, it shall price the QIAGEN IVD in a manner consistent with market norms for the pricing of companion diagnostic products. 

  

	8.3	Regulatory Approvals. QIAGEN shall be responsible for obtaining and maintaining, [**], Regulatory Approvals for the QIAGEN IVD in any Major Markets identified by Tokai in a Project Schedule, as well as any other
Markets that are mutually agreed by the Parties in a Project Schedule. Tokai shall be responsible for obtaining Regulatory Approvals for the Tokai Product. Without limiting the foregoing, QIAGEN shall use commercially reasonable and diligent efforts
to: [**], (e) at Tokai’s request, permit Tokai to participate in scheduled meetings with Governmental Authorities in each Major Market regarding development of the Tokai Product for use with the QIAGEN IVD, (f) obtain Regulatory
Approval of the QIAGEN IVD in each Major Market and (g) support any efforts of Tokai to obtain Regulatory Approval for the Tokai Product for use with the QIAGEN IVD in each Major Market. 

 

	8.4	Manufacture and Supply of IVDs. QIAGEN shall be solely responsible for, and shall use commercially reasonable and diligent efforts to, manufacture QIAGEN IVDs. QIAGEN shall manufacture the QIAGEN IVDs in
compliance with cGMP requirements. Until commercial launch of a QIAGEN IVD, QIAGEN shall ensure that adequate supplies of QIAGEN IVDs (or prototypes), are made available to Tokai, any Contract Laboratories and any Clinical Trial sites according to
the terms set forth in the Schedule. Subject to receiving sufficient notice of required quantities from Tokai, QIAGEN shall ensure that it maintains sufficient inventories of each QIAGEN IVD as is necessary for the complete conduct of the Clinical
Trials of the applicable Tokai Product and Tokai shall pay costs of all remaining quantities which cannot be used for commercialization by QIAGEN. QIAGEN shall be responsible for the transfer of the QIAGEN IVD or the prototypes thereof to the
Contract Laboratories involved in the Clinical Trials. Within a commercially reasonable time prior to launch of a Tokai Product, with reasonable advance written notice by Tokai of such launch, QIAGEN will build up and maintain at its own cost an
inventory of QIAGEN IVDs which shall be sufficient to satisfy the Commercialization requirement. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 18 

	8.5	Commercialization Term and Viability of the QIAGEN IVD. 

 (a) Once Tokai commercially
launches the Tokai Product in a Market that is a Major Market, QIAGEN shall make the QIAGEN IVD commercially available in that Major Market and use commercially reasonable and diligent efforts to Commercialize the QIAGEN IVD in that Major Market.
QIAGEN shall also Commercialize the QIAGEN IVD in any Market other than Major Markets that were agreed in a Project Schedule and for which Tokai funded the applicable Regulatory Approvals. 

(b) QIAGEN shall be responsible for Commercializing the QIAGEN IVD in each Market for as long as there are Valid Claims in that particular
Market (the “Commercialization Term”). However, QIAGEN may be sooner released from this obligation on a Market by Market basis as follows. In the event QIAGEN reasonably determines that it is not commercially reasonable to
Commercialize a QIAGEN IVD in a Market other than a Major Market (it being understood that QIAGEN shall at all times keep the QIAGEN IVD commercially available in a Major Market if the labelling for the Tokai Product in such Major Market requires
that an IVD be administered to a potential patient prior to a physician prescribing the applicable Tokai Product), QIAGEN shall provide Tokai with twelve (12) months’ written notice, which notice shall include a detailed summary of the
basis therefor. During such twelve (12) month period, QIAGEN shall use commercially reasonable efforts to procure alternative channels of distribution and make available or procure the making available of the QIAGEN IVD in such quantities and
upon commercially reasonable terms in each case as necessary to reasonably enable Tokai to market the Tokai Product in conjunction with the QIAGEN IVD. [**]. Such supply obligation shall expire upon expiration of the Commercialization Term. 

 

	9.	Management 

  

	9.1	Joint Steering Committee. Within [**] days after the Effective Date, the Parties shall form a Joint Steering Committee (the “JSC”) to facilitate the transfer of information and coordinate
processes related to the development, Regulatory Approval and Commercialization of the Tokai Products and the QIAGEN IVDs being the subject of this Agreement. The JSC shall be composed of three (3) representatives appointed by each Party. Each
representative shall be appointed (and may be replaced at any time) by a Party upon prior written notice to the other Party. These representatives shall have appropriate experience, knowledge, and ongoing familiarity with the Projects in their then
current phases. [**]. 

  

	9.2	Responsibilities. The JSC’s responsibilities shall include, but not be limited to, the following functions: 

  

	 	•	 	Facilitating the transfer of information and data related to the Commercialization and Regulatory Approval process; 

  

	 	•	 	Facilitating the cooperation of the Parties, when requested, to provide information and support; 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 19 

	 	•	 	Facilitating coordinated interpretation of data; 

  

	 	•	 	Establishing the JCC and determine how the JCC shall operate; 

  

	 	•	 	Approving each Commercialization Plan (subject to execution of the Commercial Plan by authorized signatories of the Parties); and 

  

	 	•	 	Taking such other actions as may be specifically allocated to the JSC by the Parties from time to time. 

  

	9.3	Meetings. The JSC shall meet (either in person, telephonically or via video conference) not less than once per calendar quarter or at such greater frequency as agreed by the respective committee members. Meetings
of the JSC shall be at such locations as the Parties agree. Additional representatives of the Parties may from time to time be invited to attend JSC meetings, subject to the other Party’s prior consent which shall not be unreasonably withheld.
The chair of the JSC shall alternate between a representative of Tokai and a representative of QIAGEN. All decisions of the JSC require the approval of a majority of each Party’s representatives to the JSC. 

 

	9.4	Joint Project Team. 

 Within [**] days after last signature of this Agreement the Parties
will, in addition to the JSC, form a joint project team (the “Joint Project Team” or “JPT”), which shall be responsible for facilitating the operational tasks and providing updates on the status of the Development
Project. Members of the JPT can include but shall not be limited to representatives with expertise in research biology, translational medicine, clinical, regulatory, and/or product development. Each Party will designate a representative as JPT Lead.
Such JPT shall meet, either in person, via telephone or video conferences, on a regular basis, however, at least once per month. [**]. 
  

	9.5	Joint Project Team Responsibilities. 

 The JPT’s primary responsibilities shall
include, but shall not be limited to, the following functions or roles: 
  

	 	•	 	Serving as technical lead and principal point of contact for all matters set forth in the Schedules; 

  

	 	•	 	Overseeing project planning and progress and coordinating all activities set forth in the Schedules; 

  

	 	•	 	Recommending updates to the Schedules including tactics and risk mitigation to the JSC; 

  

	 	•	 	Leading meetings (at least monthly) to facilitate review and coordinated interpretation of data, information sharing, and timeline monitoring; 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 20 

	 	•	 	Facilitating issue resolution at the Team level and escalating issues to the JSC; and 

  

	 	•	 	Coordinating with the Alliance Managers to provide input to the agenda, preparing thoroughly for meetings, attending meetings and ensuring follow up on action items. 

 

	9.6	Alliance Manager. 

 To manage the Activities under the Agreement, an alliance manager for
each Party (the “Alliance Manager”) shall be appointed by each Party. The Alliance Manager will be an associated member of the JSC and: 
  

	 	•	 	Serve as central point of contact; 

  

	 	•	 	Manage the administrative aspects related to the Agreement; 

  

	 	•	 	Manage and coordinate the different Activities under the contract and ensure appropriate communication and information among the Parties; 

 

	 	•	 	Ensure, together with the JPT, JCC and JSC, that timelines and milestones are defined appropriately and linked with respective payment schedules; and 

 

	 	•	 	Support the resolution of conflicts. 

  

	9.7	Joint Commercialization Committee. At least [**] prior to the date on which the first Regulatory Approval of a Tokai Product is expected, the Parties will form a joint commercialization team (the
“JCC”), which shall be responsible for: 

  

	 	•	 	Facilitating the transfer of information and coordination of processes related to the Commercialization of the Tokai Product and QIAGEN IVD; 

 

	 	•	 	Reviewing each Commercialization Plan prior to submission to the JSC for approval; 

  

	 	•	 	Coordinating planned sales and marketing activities, including launch strategies for the Markets, sales force activities, marketing strategies, alignment of package inserts, instructions for use, data sheets, marketing
material, publications, training activities, reimbursement strategies, sharing of market research information and use of advisory boards/key opinion leaders; and 

  

	 	•	 	Forecasting and measuring sales and distribution data to ensure adequate supply of the QIAGEN IVD in each Market. 

The JCC shall be constituted and shall operate as the JSC determines. [**]. 

 

	10.	Term and Termination 

  

	10.1	Term. This Agreement shall come into force on the Effective Date and shall continue until the expiration or termination of any and all Projects that have been executed within the Initiation Period, or until this
Agreement terminated in accordance with this Article 10 (“Term”). 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 21 

	10.2	Termination for Cause 

  

	10.2.1	Material Breach 

 (a) This Agreement 

Either Party may terminate this Agreement immediately upon sixty (60) days’ prior written notice if the other party commits a
material breach of the Agreement and fails to cure such breach within the notice period. For clarity, a breach that is specific to a Project shall not serve to terminate this Agreement, but shall be addressed as set forth below. Any termination of
this Agreement shall automatically terminate any Project Schedules, Commercialization Plans, or related agreements that may be in effect, unless the Parties agree otherwise in writing. 

(b) A Project 
 Either
Party may terminate a Project (Schedule or Commercialization Plan, as the case may be) immediately upon sixty (60) days’ prior written notice if the other party commits a material breach of the Schedule and fails to cure such breach within
the notice period. 
  

	10.2.2	Insolvency or Bankruptcy. Either Party may terminate this Agreement and any Schedules immediately by written notice to the other Party, if the other Party becomes insolvent, makes or has made an assignment for
the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy instituted on behalf of or against it (except for involuntary bankruptcies which are dismissed within ninety (90) days) or has a receiver or trustee
appointed for substantially all of its property. 

  

	10.3	Termination without Cause. Tokai may terminate this Agreement or a Schedule for any Project, for any reason or no reason, at any time upon one hundred eighty (180) days’ prior written notice to QIAGEN.

  

	10.4	Effects of Termination. In the event of a termination for cause under Section 10.2 or without cause under Section 10.3, with regard to the terminated Project(s): 

 

	 	(i)	the Parties shall promptly meet to prepare a close-out Schedule, 

  

	 	(ii)	Tokai shall make a final payment to QIAGEN for: (A) a pro rata portion of any future milestone payments where work was properly performed toward the agreed milestone(s) prior to the date of the termination notice;
(B) any project-specific inventory of the QIAGEN IVD maintained in accordance with this Agreement; (C) any pass-through costs that were already paid, or ordered and unable to be cancelled, by QIAGEN pursuant to the Schedule or as otherwise
authorized by Tokai; 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 22 

	 	(iii)	upon settlement of all financial obligations of Tokai to QIAGEN, Tokai shall have the right to issue a last order within 14 calendar days as of the effective date of termination and QIAGEN shall transfer to Tokai,
within the normal lead time for the quantity ordered after receipt of such last order from Tokai, the quantities of QIAGEN IVDs as ordered by Tokai to enable Tokai to complete the respective Clinical Trial(s), whereas Tokai shall pay for such QIAGEN
IVDs the price equalling the market price QIAGEN offers to its third party customers for such types of IVDs; 

  

	 	(iv)	all licenses to Background Intellectual Property granted by either Party under this Agreement shall terminate (for the terminated Project, or this Agreement, if terminated in its entirety) upon the effective date of
such termination; and 

  

	 	(v)	finally, only in the event of a termination by Tokai for material breach of this Agreement by QIAGEN under Section 10.2 (and specifically not where Tokai terminates this Agreement without cause) or for the
bankruptcy or insolvency of QIAGEN under Section 10.2, all licenses to Data and Foreground Intellectual Property granted by either Party under Sections 7.2 and 7.3 shall survive any expiration or termination of this Agreement.

  

	10.5	Wind-down Costs 

 In the event of a termination for cause by QIAGEN under
Section 10.2 or termination without cause by Tokai under Section 10.3, with regard to the terminated Project(s), Tokai shall reimburse QIAGEN’s costs in winding down the Project, which shall be calculated as follows: An amount equal
to the number of QIAGEN personnel who were actively engaged in performing Activities in support of the Development Project at the time of termination, multiplied by the percentage of their time allocated to the Development Project at that time,
multiplied by a daily FTE rate of US$[**] for the period of Business Days from the date of notice of termination until the date the QIAGEN personnel are reallocated to other activities or projects, not to exceed [**] days. 

 

	10.6	Return of Materials and Confidential Information. At the earlier of completion or termination of a particular Project (or this Agreement as a whole), and except as otherwise permitted herein, each Party shall
destroy, or return at the other Party’s expense and election, Materials and Confidential Information of the other Party. A Party may retain one copy of Confidential Information of the other Party for the purpose of evidence. The return or
destruction of Materials and Confidential Information will not affect the receiving Party’s obligation to observe the confidentiality and non-use restrictions set out in this Agreement. The provisions of this Section 10.5 shall not apply
to copies of electronically exchanged Confidential Information made as a matter of routine information technology backup and to Confidential Information or copies thereof which must be stored by the receiving Party according to provisions of
mandatory law. 

  

	10.7	 Survival. Termination or expiration of this Agreement will not relieve either Party of any liability which accrued hereunder prior to the
effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder at law or 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 23 

	 	
in equity with respect to any breach of this Agreement, nor prejudice either Party’s right to obtain performance of any obligation arising hereunder. Sections 3 [Materials and Records], 5
[Payment], 6 [Confidentiality], 7.2 [Assignment and License Back of Data], 7.3.2 [QIAGEN Foreground Intellectual Property], 7.3.3 [Joint Foreground Intellectual Property], 10.4 [Effects of Termination], 10.5 [Wind-down Costs], 10.6 [Return of
Materials and Confidential Information], 10.7 [Survival], 11.4.3, 11.5 [Disclaimers] 12 [Indemnification, Liability and Insurance], and 13 [Miscellaneous], shall survive any termination or expiration of this Agreement. In addition, any other
provisions which by their nature are understood to survive the termination or expiration of this Agreement shall so survive. 

  

	11.	Warranties and Disclaimers 

  

	11.1	General Warranties. Each Party hereby represents and warrants to the other Party as of the Effective Date that: (i) it is a corporation duly organized, validly existing, and in good standing under applicable
laws, rules and regulations, (ii) it has obtained all necessary consents, approvals and authorizations of all governmental authorities (both inside and outside the Markets) and other persons required to be obtained by it in connection with this
Agreement, (iii) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on its part, and (iv) it has, to its knowledge, the right to grant the applicable rights and licenses
provided for under this Agreement. 

  

	11.2	No Inconsistent Agreements. Each Party hereby represents, warrants and covenants to the other Party that during the Term of a Project it will not grant or convey to any third party any right, license or interest
in any Intellectual Property that is inconsistent with the rights and licenses expressly granted to the other Party under this Agreement with respect to the relevant Project. 

 

	11.3	No Debarment Nor Prohibited Payments. Each Party hereby certifies that it will not employ or otherwise use and has not employed or used in any capacity the services of any person (i) debarred by, or
(ii) to the best of the respective Party’s knowledge, currently subject to a debarment procedure by US Food and Drug Administration (FDA) under Title 21 United States Code Section 335a or any other competent authority in performing
any activities under this Agreement. Each Party further represents and warrants that in connection with the subject matter of this Agreement: (i) none of its employees, agents, officers or directors is a Foreign Official as defined in the U.S.
Foreign Corrupt Practices Act, (ii) it will not make, accept or request any payment, either directly or indirectly, of money or other assets to any third party where such payment would constitute violation of any law, including the U.S. Foreign
Corrupt Practices Act and the UK Bribery Act 2010, (iii) regardless of legality, it shall neither make, accept nor request any such payment for the purpose of improperly influencing the decisions or actions of any third party, and (iv) it
shall report any suspected or actual violation of this Section 11.3 to the other Party upon becoming aware of the same. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 24 

	11.4	Compliance. 

  

	11.4.1	Each Party shall perform all work performed as part of the contractual relationship with the other Party in a manner consistent with all applicable laws and regulations, including, but not limited to, all applicable
anti-bribery and antitrust laws. To the extent related to this Agreement, each Party represents and warrants that it has not made or provided, and will not make or provide, any payment or benefit, directly or indirectly, to government officials,
customers, business partners, healthcare professionals or any other person in order to secure an improper benefit or unfair business advantage, affect private or official decision-making, affect prescription behaviour, or induce someone to breach
professional duties or standards. 

  

	11.4.2	Each Party will immediately report to the other Party in writing any suspected or detected violation of the above principles in connection with the other Party’s business and, in such cases, will cooperate fully
with the other Party in reviewing the matter. In the event that a Party believes, in good faith, that the other Party has violated any of the above principles; then such Party shall have the unilateral right to terminate the contractual relationship
with the other Party with immediate effect. 

  

	11.4.3	During the Term and for the one (1) year period following the termination or expiration of this Agreement, each Party through a mutually agreeable, independent third-party auditor, upon reasonable advance notice to
and at the auditing Party’s sole expense, shall have the right during normal business hours to examine and review such books, records, and other documents and materials, except individual salary information, for the sole purpose of verifying
whether the other Party has complied with the compliance obligations stated in this Section 11.4. 

  

	11.5	Disclaimers. THE REPRESENTATIONS AND WARRANTIES SET FORTH ABOVE ARE IN LIEU OF ANY AND ALL OTHER WARRANTIES AND REPRESENTATIONS, EXPRESS, IMPLIED, OR STATUTORY, AND EACH PARTY HEREBY DISCLAIMS ANY AND ALL
WARRANTIES OR REPRESENTATIONS, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR FOR NON-INFRINGEMENT OF A PATENT, TRADEMARK OR OTHER INTELLECTUAL PROPERTY RIGHTS.

  

	12.	Indemnification, Liability and Insurance 

  

	12.1	 Indemnification by QIAGEN. QIAGEN shall defend, indemnify and hold harmless each of Tokai, its Affiliates and their respective directors,
officers, employees and agents, together with the successors and assigns of any of the foregoing (each, a “Tokai Indemnitee”) from and against any and all third party claims, suits, actions, demands or judgments (collectively,
“Claims”) to the extent that such Claims arise, directly or indirectly out of or in connection with this Agreement, and any and all resultant liabilities, damages, settlements, penalties, fines, costs or expenses (including
reasonable attorneys’ fees) (“Liabilities”) to the extent that such Claims and Liabilities arise out of, or in connection with: (i) a QIAGEN Indemnitee’s negligence or willful misconduct, (ii) a QIAGEN
Indemnitee’s violation of applicable law, rule or regulation, (iii) the breach by QIAGEN of any of its representations, warranties and/or covenants under Article 11, (iv)

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 25 

	 	
personal injury or death caused by QIAGEN’s use, storage or handling of the Materials in violation of this Agreement, (v) personal injury or death caused by the use or administration of
a QIAGEN IVD hereunder and (vi) the infringement of third party Intellectual Property as a result of the Commercialization of any QIAGEN IVD (other than third party Intellectual Property covering biomarkers); provided, however,
that QIAGEN’s obligations under this Section 12.1 shall be excused to the extent that such Liabilities arise out of a Claim to which a QIAGEN Indemnitee is entitled to indemnification under Section 12.2. 

 

	12.2	Indemnification by Tokai Pharmaceuticals. Tokai shall defend, indemnify and hold harmless each of QIAGEN, its Affiliates, and their respective directors, officers, employees and agents, together with the
successors and assigns of any of the foregoing (each, a “QIAGEN Indemnitee”) from and against any and all Claims to the extent that such Claims arise, directly or indirectly out of or in connection with this Agreement, and any and
all resultant Liabilities, to the extent that such Claims and Liabilities arise out of, or in connection with: (i) a Tokai Indemnitee’s negligence or willful misconduct, (ii) a Tokai Indemnitee’s violation of applicable law, rule
or regulation, (iii) the breach by Tokai of any of its representations, warranties and or covenants under Article 11, and (iv) personal injury or death caused by the use or administration of a Tokai Product, (v) medical malpractice
occurring in connection with the Clinical Trials of a Tokai Product, and (vi) the infringement of third party Intellectual Property as a result of the Commercialization of any Tokai Product alone, or third party Intellectual Property covering
biomarkers as a result of the Commercialization of the QIAGEN IVD; provided, however, that Tokai’s obligations under this Section 12.2 shall be excused to the extent that such Liabilities arise out of a Claim to which a Tokai
Indemnitee is entitled to indemnification under Section 12.1. 

  

	12.3	Procedure. A Party seeking indemnification under Section 12.1 or Section 12.2 (an “Indemnitee”), shall notify the other Party (the “Indemnitor”) upon becoming aware of
any Claim that may be subject to indemnification under this Article 12. Failure to provide such notice shall not constitute a waiver or release of the Indemnitee’s rights to indemnification, except to the extent that such delay or failure
materially prejudices the Indemnitor. The Indemnitor shall have the right, (but not the obligation) to control the defense and disposition (including, without limitation, settlement, litigation or appeal) of any such claim. The Indemnitee shall
cooperate reasonably with the Indemnitor and its legal representatives in connection with the investigation and defense of any Claim and/or Liability covered by this Article 12. Indemnitor shall not settle any indemnified claim hereunder in a manner
that establishes liability on the part of any Indemnitee, without the express written consent of such Indemnitee. The Indemnitor shall have no obligation to indemnify any Indemnitee with respect to any claim settled without the prior written consent
of the Indemnitor. 

  

	12.4	Limitation of Damages. NEITHER PARTY WILL BE LIABLE TO THE OTHER FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER SIMILAR DAMAGES (INCLUDING ANY CLAIMS FOR LOST PROFITS
OR REVENUES) ARISING FROM OR RELATING TO THIS AGREEMENT; PROVIDED, HOWEVER, THAT THIS SHALL NOT LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY WITH RESPECT TO ANY THIRD PARTY CLAIMS UNDER THIS ARTICLE 12.

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 26 

	12.5	Insurance. During the Term and until completion of the last Project conducted under this Agreement, each Party shall maintain a comprehensive commercial general liability insurance program as is customary for
diagnostic or pharmaceutical companies (as the case may be), including product liability insurance with coverage limits not less than US$[**] for each occurrence and in the aggregate. Tokai also will maintain clinical trials liability coverage with
limits not less than US$[**] for each occurrence and in the aggregate, and will name QIAGEN as an additional insured. All insurers utilized to confirm coverage within Section 12.5 shall be rated A, Class VII or better by A.M. Best Company in a
form satisfactory to both Parties. Upon request, each Party will provide to the other Party respective insurance certificates. For clarification, the insurance coverage required herein may be provided through any reasonable structure of local and
global insurance programs. 

  

	13.	Miscellaneous 

  

	13.1	Force Majeure. Neither Party shall be liable for failure or delay in performance under this Agreement due to causes such as an act of God, strike, lockout or other labor dispute, civil commotion, sabotage, fire,
flood, explosion, acts of any government, any other similar causes not within the reasonable control of the Party affected (a “Force Majeure Event”). In the event either Party is unable to perform any of its obligations hereunder
due to a Force Majeure Event, such Party shall promptly notify the other Party. Performance hereunder shall be promptly resumed after the applicable Force Majeure Event has been remedied. 

 

	13.2	Notice. All notices under this Agreement shall be in writing and shall be sent by registered or certified mail, postage prepaid, or by overnight courier service, to the attention of the Legal Department in the
case of QIAGEN, and to the attention of the Chief Operating Officer in the case of Tokai, in each case at the addresses of the respective Parties set forth in the first paragraph of this Agreement. 

 

	13.3	Governing Law and Disputes. 

  

	13.3.1	Law. The formation, existence, performance, validity and all aspects of this Agreement shall be governed by and construed in all respects in accordance with the laws of the State of the New York, USA without
regard to its rules on conflicts of laws. 

  

	13.3.2	 Dispute Resolution. Prior to arbitration, the parties shall seek informal resolution of disputes. The process shall be initiated with written
notice of one party to the other, describing the dispute with reasonable particularity followed with a written response within [**] calendar days of receipt of notice. Each party shall promptly designate an executive with requisite authority to
resolve the dispute. The informal procedure shall commence within [**] calendar days of the date of response. If the dispute is not resolved within [**] business days of the date of commencement of the procedure, either party may proceed to binding
arbitration without recourse to the ordinary courts of law according to the American Arbitration Association (the “Rules”). The seat of arbitration shall be New 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 27 

	 	
York, New York USA. The number of arbitrators shall be three (3). The arbitrators shall be appointed in accordance with the Rules. The language to be used in the arbitration proceedings shall be
English. If any arbitration is brought for the enforcement of this Agreement, or because of any alleged dispute, breach, default or misrepresentation in connection with any of the provisions of this Agreement, the successful or prevailing party
shall be entitled to recover reasonable attorneys’ fees and other costs incurred therein, in addition to any other relief to which it or they may be entitled. Notwithstanding anything to the contrary in this Section, if either Party in its sole
judgment believes that any such breach of this Agreement could cause it irreparable harm, such Party (i) will be entitled to seek equitable relief in order to avoid such irreparable harm, and (ii) will not be required to follow the
procedures set forth in this Section 13.3.2 with respect to seeking such relief. 

  

	13.4	Entire Agreement. This Agreement sets out the entire agreement and understanding between the Parties regarding the subject matter of this Agreement and supersedes all prior discussions, arrangements and
agreements, whether oral or in writing or which may be inferred from the conduct of the Parties, including without limitation the Initiation Agreement dated October 29, 2014 between the Parties. 

 

	13.5	Validitv/Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision which shall remain in full force and effect. The
Parties undertake to replace such invalid or unenforceable provision by a valid and enforceable provision which accomplishes as far as possible the purpose and the intent of the invalid or unenforceable provision. 

 

	13.6	Assignment. This Agreement may be freely assigned by either Party to any of its’ Affiliates. This Agreement shall not be assigned by either Party to a third party, except (i) with the other Party’s
prior written approval, which approval shall not be withheld unreasonably, or (ii) by reason of any merger, acquisition, reorganization, or consolidation to any successor in interest of the business to which this Agreement relates. Other than
as provided by this Section 12.6, any attempt by either Party to effect an assignment without the consent of the other Party will be void and without effect. 

 

	13.7	Waiver; Modification of Agreement. No waiver, amendment, or modification of any of the terms of this Agreement shall be valid unless in writing and signed by authorized representatives of both Parties. Failure by
either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor shall a waiver by either Party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances.
Any amendments to this Agreement shall be made in writing; the same applies for any waiver or amendment of this written form clause. 

  

	13.8	Relationship of the Parties. The relationship of the Parties is that of independent contractors. 

  

	13.9	Independent Development. Nothing in this Agreement will be construed as restricting either Party’s ability to acquire, license, develop, manufacture or distribute for itself, or have others acquire, license,
develop, manufacture or distribute for such Party, similar technology performing the same or similar functions as the technology contemplated by this Agreement, or to market and distribute such similar technology in addition to, or in lieu of, the
technology contemplated by this Agreement, provided, however, that such activities of such Party comply with all provisions herein. 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 28 

	13.10	Execution In Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.
Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (.pdf) sent by electronic mail shall be deemed to be original signatures. 

 

	13.11	No Third Party Beneficiaries. No person other than Tokai or QIAGEN (and their respective affiliates and assignees) shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of
this Agreement. 

 [signature page follows] 

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 29 

 IN WITNESS WHEREOF, QIAGEN and Tokai, intending to be legally bound, have executed this Agreement
at the dates indicated below by their respective duly authorized representatives. 
  

									
	Tokai Pharmaceuticals, Inc.				QIAGEN Manchester Limited
					
	By:		 /s/ John McBride
				By:		 /s/ Douglas Liu

	Name:		John McBride				Name:		Douglas Liu
	Title:		CEO				Title:		Senior VP Global Operations
					
	Date:		January 12, 2015				Date:		  

  
 Confidential and
Proprietary Information of Tokai and QIAGEN 
  
 30 

 Companion Diagnostics 

PROJECT WORK PLAN 
  

			
	Between		TOKAI PHARMACEUTICALS, INC.
			One Broadway, 14th Floor
			 Cambridge, MA 02142
 hereinafter “
TOKAI “

		
	and		QIAGEN Manchester Limited
			Skelton House, Lloyd Street North
			Manchester, M15 6SH,
			 England
 hereinafter
“QIAGEN”

 This Project Schedule 1 (this “Schedule”) is dated March 13, 2015 (the “Schedule Effective
Date”), and is incorporated into the Master Collaboration Agreement dated January 12, 2015 by and between TOKAI and QIAGEN (for the purposes of this Schedule, the “MCA”), and describes a Project to be conducted under the
terms of the MCA, including, without limitation, a list of Activities, the TOKAI Compound (“Galeterone”) and the QIAGEN IVD development timelines, Deliverables, Markets and other terms applicable to a Development Project. The Project was
initiated under an Initiation Agreement dated October 29, 2014 (“Initiation Agreement”), which shall be superseded by this Schedule. All capitalized terms used and not expressly defined in this Schedule will have the meanings given to
them in the MCA. 
 This Schedule is divided into the following seven (7) sections: 

 

	 	1.	Background 

	 	2.	Activities 

	 	3.	Deliverables 

	 	4.	Timeline 

	 	5.	Key Assumptions and Requirements 

	 	6.	Compensation 

	 	7.	Additional Terms 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 1. BACKGROUND 

The party’s MCA establishes a legal framework for their collaborations in the field of development and commercialization of in vitro diagnostics
and/or companion diagnostics for TOKAI Compounds. 
 TOKAI wishes to have QIAGEN develop and commercialize a companion diagnostic to identify patients
carrying Androgen Receptor Exon 9 Xq12 (AR-V7) splice variant in Castration Resistant Prostate Cancer (CRPC) for treatment with the TOKAI Compound (for purposes of this Schedule, the “QIAGEN IVD”). 

The scope of this Project is for development of the QIAGEN IVD necessary for co-development and clinical validation together with the TOKAI Compound,
designated for approval and Commercialization in the US, EU, Canada and Australia. While Japan is not included within the scope of this Project due to an evolving regulatory landscape in this country, at TOKAI’s request the Parties shall
negotiate diligently and in good faith the terms under which the scope of this Project would be expanded to include potential Commercialization of the QIAGEN IVD together with the TOKAI Compound in Japan. 

2. Activities 
 TOKAI responsibilities

 In relation to the development of the QIAGEN IVD, TOKAI shall be responsible for the following: 

 

	 	•	 	TOKAI shall solely be responsible for the clinical testing of Galeterone and proper use of the QIAGEN IVD by the central laboratories in connection with such clinical testing. 

 

	 	•	 	TOKAI shall provide QIAGEN clinical data, including sample and patient demographic data, regarding the use of the QIAGEN IVD as well as patient outcome data to the extent such data is available and necessary, as
reasonably determined by QIAGEN, for QIAGEN regulatory filings for the QIAGEN IVD and for planning of further QIAGEN IVD development activities at QIAGEN in the performance of the Development Project. TOKAI will be responsible for contracting out
the clinical sample testing to and providing oversight of a suitable GCP-compliant central laboratory clinical testing site (“Laboratory Site”) and QIAGEN will support the selection, training and qualification of this vendor. For
clarification, notwithstanding any provision in the MCA, the parties expressly agree that Tokai shall be responsible for the Milestone Payments set forth below and costs set forth in Attachment 3 which relate to applications for Regulatory Approval
of the QIAGEN IVD. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

	 	•	 	TOKAI will make reasonable efforts to provide any clinical samples necessary for QIAGEN IVD development and verification/validation. QIAGEN will work with its approved procurement service providers to source appropriate
samples. Sample costs will be passed through to TOKAI. 

 QIAGEN responsibilities 

Subject to and without limiting the terms and conditions of the Agreement, QIAGEN shall be responsible for the development of the QIAGEN IVD as follows. 

 

	 	•	 	QIAGEN shall lead the development and PMA submission with FDA’s Center for Devices and Radiological Health (CDRH) for the QIAGEN IVD. QIAGEN shall inform and coordinate with TOKAI on all CDRH-related matters and
support TOKAI in discussions with FDA’s Center for Drug Evaluation and Research (CDER) for Galeterone. 

  

	 	•	 	Subject to the involvement of TOKAI as described above, QIAGEN shall be responsible for the design, development and regulatory approval of the QIAGEN IVD in accordance with this Schedule, including the development of
suitable and necessary protocols for the QIAGEN IVD. 

  

	 	•	 	QIAGEN shall be responsible for manufacturing, supply and delivery of the QIAGEN IVD, including all components for the QIAGEN IVD, subject to any intellectual property considerations set forth in Section 7 below.

  

	 	•	 	QIAGEN shall be responsible for the preparation of the PMA documentation and site readiness required for submission of the PMA for the QIAGEN IVD. 

 

	 	•	 	QIAGEN shall be responsible for the intended use and applicable package insert, and the pricing, reimbursement and market access of the QIAGEN Kit, subject to the applicable terms of the MCA. 

3. DELIVERABLES 
 Stage 1 Feasibility

 [**]. Stage 1 of development is covered under the initiation agreement between QIAGEN and TOKAI which was executed on October 29, 2014. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Stage 2 Clinical Trial Assay labelled Investigational Use Only (“IUO”) 

[**]. An IUO labelled Clinical Trial Assay (“CTA”) (with or without and IDE) is required in H1 2015. [**] 

Stage 4 CDx Development and Validation 
 The fourth
stage of development will cover all of the activities needed for the development and approval of a CDx assay in the USA, Canada, EU and Australia. This stage will include all Design Verification and Clinical Validation Studies 

Stage 5 CDx Approval and Product Implementation 

Product Implementation into the US will follow approval of the PMA approval and agreement on the device labelling with CDRH 

For the EU development data used to support the US PMA application will be used to generate a technical file in compliance with the Essential Requirements
Checklist. The MHRA shall be notified of the new product under the self-certification scheme. Appropriate labeling and translations will be prepared as necessary for EU countries accepting the CE Mark. 

For Canada it is also assumed that data used to support the US PMA application will be used to complete the necessary requirements as established by Health
Canada for successful submission and approval. Product Implementation will follow and establish the product in the Canadian market with appropriate labelling and translations as necessary. 

For Australia it is also assumed that data used to support the US PMA application will be used to complete the necessary requirements as established by the
Australian Therapeutic Goods Administration (TGA) for successful submission and approval. Product Implementation will follow. 
 Contractual Milestone
Description 
 The Project Agreement will be delivered on a completed milestone based model. The following descriptions provide a high level overview
of the work package and the deliverable for acceptance and completion. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Milestone 1: Assessment of Technology for Transfer 

This milestone will involve site-visit preparation, evaluation and assessment of the existing work undertaken by Dr. Jun Luo and associates at Johns
Hopkins University (“JHU”) for information exchange. 
 Evidence of Milestone Achievement: Short report on findings and recommendations for
technology transfer. 
 Note: This Milestone 1 was completed under the Initiation Agreement. 

Milestone 2: Design Control Planning (CDx) 

This milestone represents the initial activities associated with the Companion Diagnostic Development process for the AR-V7 splice variant [inclusive of AR-FL]
assay. 
 For this milestone, the following design control documents will be signed off and provided as evidence of Milestone achievement: 

[**]. 
 Milestone 3: Feasibility; Conversion of AR-V7
[inclusive of AR-FL] splice variant assay to a QIAGEN format & formulation for use on the Rotor-Gene Q MDx 
 [**]. 

Milestone 5: Clinical Trial Assay Build Completion (Including CTA QC and Control Specifications) 

This milestone entails activities required to complete development of the Clinical Trial Assay for use in Phase III Clinical Trial. The assay is planned to be
presented to CDRH under an Investigational Device Exemption application. The following work packages will be competed; 
 [**]. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Milestone 6: Lab Set-up for Clinical Trial Testing (6a,6b, & 6c US, EU &
Asia) 
 [**] 
 Milestone 8:
Completion of Design Inputs; Design Input Lock and Design & Development Plan (CDx) 
 [**]. 

Milestone 9: Completion of Assay Optimization and Specification Setting for CDx 

[**]. 
 Milestone 10: Prototype Batch
Manufacturing (CDx) – needed for assay performance studies 
 [**] 

Milestone 12: CDx Assay Performance Studies Complete 

[**] 
 Milestone 13: Assay Software Available

 [**] 
 Milestone 14: Completion of
Verification Batches (Pilot Batches) 
 [**] 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Milestone 15: System Design Lock;  

[**] 
 Milestone 17: Design Output and Design
Verification Lock (Completion of Verification) 
 [**] 

Milestone 20: PMA Approval 
 This milestone will be
triggered upon successful approval of the companion diagnostic 
 Evidence of Milestone Achievement; Receipt of successful notification letter by
CDRH 
 Milestone 21: Product Implementation 

[**]. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 4. TIMELINE 

TOKAI—Updated Gantt Chart Based on start date of 28th October 2014 

[**] 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 5. KEY ASSUMPTIONS AND REQUIREMENTS 

Tokia and QIAGEN each recognize that this Schedule has been prepared on the basis of a number of Key Assumptions as described in this Section 5.
During the course of the Development Project, a change in an assumption upon which this Schedule is based may require a change to modify the scope of the project, and the Parties agree to address such changes in good faith pursuant to the process
provided under Section 2.3 of the MCA. Regulatory 
 An IDE may be required by FDA. This shall be dependent on FDA’s response to the Risk
Determination Document. 
 Study Estimates 

Tokia estimates screening approximately [**] patients to enroll a total of 150 AR-V7 positive patients into the clinical trial. Patient screening and selection
is planned to begin as soon as possible in H1 2015 
 Clinical Samples 

TOKAI will work with Johns Hopkins University and other parties to supply QIAGEN with clinical samples to support the development and verification of the AR-V7
assay 
  

	•	 	QIAGEN will make all best efforts to procure representative samples for development and analytical validation of the assay. However, the availability of samples containing specific splice variants cannot be guaranteed.

  

	 	(1)	QIAGEN shall not be held responsible for any delays caused by insufficient supply or other issues with the third party sample providers. 

 

	 	(2)	Any such samples shall be considered “pass-through costs” and shall be paid in full by TOKAI upon invoice from QIAGEN. 

 

	•	 	The development of any specialized sample material e.g. cell lines containing specific splice variants are not included in this project plan and costing. The development of specialized sample material would be
considered as pass through costs to TOKAI. These pass through costs are outlined as estimated in Attachment 2. 

  

	•	 	Samples from the AR-V7 trial need to be retained for the purposes of any bridging studies. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Territory 

The Territory for this Development Project shall include the Markets listed on Attachment 1 to this Schedule. 

6. MILESTONE PAYMENTS 
 The following Milestones and
Deliverables shall be completed by QIAGEN to the satisfaction of TOKAI in accordance with the terms of Section 2 of the MCA. Payment for completed Milestones will be made in accordance with Section 5 of the MCA and with the additional
process as follows: (1) Tokai shall approve or dispute milestone completion within [**] business days of receiving QIAGEN’s report; (2) Tokai agree to review milestone four within [**] business days of receiving QIAGEN’s report;
(3) if Tokai fails to approve or dispute the milestone completion within such time period, the milestone completion shall be considered approved; (4) if Tokai disputes the milestone completion, the parties shall work in good faith to
timely resolve the dispute. 
  

							
	 Milestone
	  	 Description
	  	Completion
Date (Est)	  	Payment
(USD)
	1	  	Assessment of Technology for Transfer	  	[**]	  	[**]
				
	2	  	Design Control Planning	  	[**]	  	[**]
				
	3	  	Feasibility Testing for AR-V7	  	[**]	  	[**]
	
	Full CDx Milestones
				
	4	  	[**]	  	[**]	  	[**]
				
	5	  	Clinical Trial Assay Build Complete (Controls and QC)	  	[**]	  	[**]
				
	6a	  	Lab set up for IUO Testing – US	  	[**]	  	[**]
				
	6b	  	Lab set up for IUO Testing – EU	  	[**]	  	[**]
				
	6c	  	Lab set up for IUO Testing – Australia	  	[**]	  	[**]
				
	7	  	[**]	  	[**]	  	[**]
				
	8	  	Design Input Lock & DDP	  	[**]	  	[**]
				
	9	  	Completion of Assay Optimization and Specification Setting for CDx	  	[**]	  	[**]
				
	10	  	Prototype Batch Manufacture	  	[**]	  	[**]
				
	11	  	[**]	  	[**]	  	[**]

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

							
				
	12		CDx Performance Studies Complete		[**]		[**]
				
	13		Assay Software Available		[**]		[**]
				
	14		Completion of Verification Batches (Pilot Batches)		[**]		[**]
				
	15		System Design Lock		[**]		[**]
				
	16		[**]		[**]		[**]
				
	17		Design Output and Verification Lock Completion of Assay Verification		[**]		[**]
				
	18		[**]		[**]		[**]
				
	19		[**]		[**]		[**]
				
	20		PMA Approval		[**]		$1,000,000
				
	21		Product Implementation		[**]		[**]
				
	Total						[**]

 [**]. 

7. ADDITIONAL TERMS 
 7.1 Project Term

 The Project Term of this Project shall commence on the Schedule Effective Date and continue until all commercialization obligations expire under
Section 8 of the MCA, unless sooner terminated by either Party under the terms of the MCA. 
 7.2 Technology and Intellectual Property
Considerations 
 (a) Circulating Tumor Cells Technology Access Fee 

[**]. 
 (ii)
Scope of Technology Access 
 In exchange for the Technology Access Fee described above and notwithstanding anything in Section 7
of the to the contrary, QIAGEN will grant, and hereby does grant, TOKAI the exclusive right to have QIAGEN utilize the CTC Technology in the field of companion diagnostics for the TOKAI Compound. For clarity, the CTC Technology shall be considered
the “Background Intellectual Property” of QIAGEN under the MCA. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 (iii) Technology Access Fee 

The Technology Access Fee shall be US $[**]. QIAGEN shall invoice Tokai for this amount promptly upon [**]. TOKAI shall pay the invoice within
[**] days of receipt. [**] 
 (b) JHU Sublicense 
  

	 	(i)	“JHU License” shall mean that certain Exclusive License Agreement dated January 9, 2015 between The Johns Hopkins University (“JHU”) and TOKAI, a copy of which is attached hereto as
Attachment 4. 

  

	 	(ii)	The Licensed Patents and Licensed Know-How (each as defined in the JHU License) shall be considered TOKAI’s Background Intellectual Property. 

 

	 	(iii)	QIAGEN specifically acknowledges and agrees that, in accepting the grant of certain of the licenses under the MCA, it shall be sublicensed under the Licensed Patents and Licensed Know-How and, as such, QIAGEN shall be
subject to and shall assume certain terms and conditions of the JHU License (as such agreement may be amended from time to time and communicated to QIAGEN) as if those terms and conditions were imposed on QIAGEN itself. These terms and conditions
include, without limitation, due diligence, reporting and recordkeeping, indemnification, maintenance of insurance non-use of JHU’s name, and audit rights. In addition, QIAGEN may not sublicense the Licensed Patents and Licensed Know-How
sublicensed to QIAGEN without TOKAI’s and JHU’s consent. QIAGEN shall also have no right to prosecute the Licensed Patents or to defend or enforce the Licensed Patents. In the event of any conflict or inconsistency between any applicable
provision of this Agreement and the provisions of the JHU License, the provisions of the JHU License shall prevail. Without limiting the foregoing, QIAGEN shall be subject to Sections 7, 8, 10.3 and 12.2 of the JHU License, which terms are
incorporated by reference herein. 

  

	 	(iv)	QIAGEN acknowledges and agrees that TOKAI may provide JHU an unredacted copy of the sections within the MCA and this Project Agreement which are strictly related to the sublicensing of third party intellectual property,
and to disclose such information related to the conduct of the Project to the extent reasonably necessary for TOKAI to fulfil its reporting obligations to JHU under the JHU License. In the event TOKAI is required to disclose QIAGEN’s
Confidential Information to JHU in order to fulfil its obligations under the JHU License, TOKAI shall provide QIAGEN with advance notice of any such disclosures. TOKAI will reasonably consider any comments that QIAGEN may have on the scope of such
disclosure. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

	 	(v)	For so long as QIAGEN is commercializing a QIAGEN IVD, it shall provide TOKAI, within [**] days following completion of each calendar quarter, a written report detailing, on a country by country basis, aggregate Net
Revenues (as defined in the JHU License) of each QIAGEN IVD during the preceding calendar quarter in sufficient detail for TOKAI to calculate and remit royalties due to JHU under the JHU License. Such reports shall be considered the highly
confidential information of QIAGEN and shall not be disclosed or used for any purpose other than calculating the royalty obligation under the JHU License. Without limiting the foregoing, such reports shall include Net Sales Revenues (as defined in
the JHU License) and all deductions and adjustments that may be applicable to a calculation of Net Revenues. QIAGEN shall make itself reasonably available to answer any questions that TOKAI may have on the foregoing royalty reports in sufficient
time for TOKAI to fulfill its reporting and payment obligations to JHU. 

  

	 	(vi)	TOKAI shall be responsible for the timely payment of all royalty obligations to JHU under the JHU License. TOKAI shall defend, indemnify and hold harmless QIAGEN for any third party costs, claims, or liabilities
directly resulting from TOKAI’s failure to make royalty payments under the JHU License (except to the extent such failure is the result of QIAGEN failing to fulfil its reporting obligations to TOKAI under this Agreement). 

 

	 	(vii)	TOKAI shall at all times comply with the JHU License to maintain such license in full force and effect during the term of this Agreement. TOKAI shall defend, indemnify and hold harmless QIAGEN for any third party costs,
claims or liabilities directly resulting from TOKAI’s failure to comply with the JHU License (except to the extent such failure is the result of QIAGEN failing to fulfil its obligations to TOKAI under this Agreement). 

IN WITNESS WHEREOF, QIAGEN and TOKAI, intending to be legally bound, have executed this Agreement at the dates indicated below by their respective duly
authorized representatives. 

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

									
	TOKAI Pharmaceuticals, Inc.				QIAGEN Manchester Limited
					
	By:		  
				By:		 /s/ Douglas Liu

	Name:						Name:		Douglas Liu
	Title:						Title:		Senior VP Global Operations QIAGEN
					
	Date:		  
				Date:		12 March 2015

  

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Attachment 1 

Territory 
 United States 

European Union 
 Canada 

Australia 

 Attachment 2 
  

					
	 Name
	  	 Description
	  	Payment
(USD)
	 Sample Procurement
	  	Procurement of CRPC samples for development and verification; may require customized project to be established with a procurement service provider to prospectively collect and ship samples	  	[**]
	 Non GMP Raw materials
	  	Non GMP oligos, Extraction Kits, PCR reagents	  	[**]
	 [**]
	  	[**]	  	[**]
	 PAX gene tubes and extractions
	  	[**]	  	[**]
	 GMP Raw materials
	  	GMP reagents [**]	  	[**]
	 Long oligonucleotides
	  	[**]	  	[**]
	 In vitro transcripts
	  	[**]	  	[**]
	 Cell Line Control Materials
	  	Procurement and culture of AR–V7 cell lines for development.	  	[**]
	 Development of reference method for accuracy
	  	A comparator method may be required to determine the Sensitivity and specificity of the assay. The requirements will be determined by discussions with CDRH	  	[**]
	 IP
	  	[**]	  	[**]
	 Materials Management Fee
	  	 Covers the development of specifications for any incoming materials such as: samples, goods receipt, labelling, database entry for
internal tracking and storage
 Final amount is dependent on final PTEs costs.
	  	[**]
	 Total (Estimate)
	  		  	[**]

  

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Attachment 3 

Registration: 
 The parties expressly
agree that Tokai shall fund all regulatory filings set forth in this Project Agreement, despite any conflicting terms in the MCA. 
  

											
	 Territory
	  	 Requirements
	  	Costs	 	Preparation	 	 	Review Clock
	 Canada
	  	 Product implementation together with IVD registration activities and submission fees for Health Canada

(Assumes no additional data generation)
	  	[**]	 	 	[	**] 	 	4-5 Months
according to
Health Canada
Guidance
	 EU- CE Mark
	  	 Product implementation with IVD registration activities for self-certification and updated filing with notified bodies

(Assumes no additional data generation)
	  	[**]	 	 	[	**] 	 	n/a –
products currently
 self-certified* 
 *
Subject to
existing
requirements and
subject to change
with new updates
as they
materialize.

	 Australia
	  	 Product implementation with IVD registrational activities and submission fees for Australian Therapeutic Goods Administration (TGA)

(Assumes no additional data generation)
	  	[**]	 	 	[	**] 	 	7-12 months
according to TGA
Guidance

  

  
 Confidential and
Proprietary Information of TOKAI and QIAGEN 
  

 Attachment 4 

JHU License 
 Incorporated by reference to
Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 

  
 Confidential and
Proprietary Information of TOKAI and QIAGENEX 10.3 31Mar15

EXHIBIT 10.3

CONFIDENTIAL EMPLOYMENT AGREEMENT
This CONFIDENTIAL EMPLOYMENT AGREEMENT (“Agreement”) is effective as of March 19, 2015 (the “Effective Date”) by and between Walter Bogumil (“Executive”) and Affinity Gaming (“Affinity”).
In consideration for the mutual promises contained herein and for other good and valuable consideration, the sufficiency and receipt of which each party expressly acknowledges, Executive and Affinity agree as follows:
1.Employment.  Affinity agrees to employ Executive as its Senior Vice President, Chief Financial Officer and Treasurer, and Executive accepts such employment upon the terms and conditions stated herein.  Executive represents and warrants that Executive is free to enter into this Agreement and is not otherwise prohibited from doing so by any contract or covenant with any person, former employer, or other entity.  Executive agrees that in performing services for Affinity, Executive will not utilize any confidential or proprietary information from any former employer.
     
2.Gaming Regulations.  Executive acknowledges that Affinity’s business is highly regulated by law and is reliant upon maintaining relevant gaming licenses where it and its affiliates conduct business, and that gaming license regulatory bodies demand very detailed personal information regarding Affinity’s officers and employees.  Accordingly, Executive acknowledges that Executive may be required to provide information regarding Executive’s background including, but not limited to, detailed financial information, criminal history, prior employment, prior residences, familial relationships, military history, and educational history.  Executive further acknowledges that such information may require the execution of one or more releases of information or other documents such that Affinity or a designated third party may obtain background information necessary for compliance with regulatory requirements. Executive expressly agrees to provide and execute releases and other documents, and otherwise fully cooperate with disclosure of any and all information required by any law or regulatory body including, but not limited to, any gaming regulatory and/or licensing body, and as may otherwise be required by Affinity.

3.Term.  Executive’s employment with Affinity shall begin on the Effective Date, and shall continue thereafter until terminated by either party in accordance with the terms set forth in Paragraph 11 below. 

4.Duties and Responsibilities.  Executive shall perform such duties as are reasonably assigned to Executive by Affinity’s Chief Executive Officer to whom Executive will report and shall be accountable.  Such duties may include, but are not limited to, such duties and responsibilities typically performed by a chief financial officer of a public company in the gaming industry, and may involve Affinity affiliates.  Executive shall devote Executive’s full time and best efforts, skill, and attention to the diligent performance and discharge of such duties and responsibilities.

5.Exclusivity and Conflict of Interest.  Executive’s employment with Affinity shall be exclusive.  Accordingly, during Executive’s employment with Affinity, Executive shall not engage in any business activity other than on Affinity’s behalf without the express written consent of Affinity’s Chief Executive Officer.  It will not be a violation of this exclusivity provision for Executive to serve as a principal and manager of Capital Funding, LLC, which Executive represents is a family-owned and operated, non-gaming, non-hospitality and predominantly residential real estate financing business, or on charitable or civic boards or committees, provided that in all cases such activities do not interfere with the performance of Executive’s duties under this Agreement.  Under no circumstance shall Executive engage in any activity that could create a conflict of interest between Executive and Affinity or any of its affiliates.  

6.Compensation.  Affinity will pay Executive an annual salary in the amount of $350,000.  This amount will be subject to periodic adjustment at Affinity’s discretion.  Affinity will pay Executive’s pro-rata salary, less customary deductions, on Affinity’s regular paydays.  

7.Incentive Bonus.   Executive is eligible to receive an annual performance-based bonus, the amount of which, if any, will be based on the achievement of certain collective and individual goals established by Affinity Gaming’s Board of Directors (the “Board”) in its sole and absolute discretion, with a target bonus of 50% of Executive’s base salary for Executive achieving 100% of the goals set for that calendar year.  Such incentive bonuses are not earned or paid on a pro-rated basis and are subject to Executive’s continued employment at the time of payment.  Such bonus, if earned and if awarded by the Board in its sole and absolute discretion, shall be paid, subject to customary deductions, on or before March 15 of the calendar year immediately following the calendar year to which the bonus pertained.

8.Long Term Incentive Plan.  Executive is eligible to participate in the Affinity Gaming 2011 Amended Long Term Incentive Plan (“LTIP”), in accordance with the terms and conditions of the LTIP and any agreement entered into in connection therewith. Affinity shall cause the Compensation Committee to provide Executive the following incentives under and subject to the terms and conditions of the LTIP:

A.  Before the end of the first quarter of 2015:
(1)    An award of 20,000 restricted shares of Affinity’s common stock (“Restricted Shares”), to vest ratably in thirds subject to the conditions set forth in Paragraph 8.C. below, on March 31 of 2016, 2017, and 2018; and
(2)    An award of 20,000 options to acquire shares of Affinity’s common stock (“Stock Options”), to vest upon Affinity achieving earnings before income tax, depreciation and amortization (“EBITDA”) of $72.5 million in any calendar year before the Stock Options expire.  The EBITDA target of $72.5 will be reasonably adjusted to account for any acquisitions or dispositions made by Affinity prior to expiration of the Stock Options; and
B.    In the first quarter of each year, 2015 through 2019, an award of 30,000 Stock Options having the following vesting schedule and conditions:
 (1)    15,000 of the Stock Options to vest ratably in thirds subject to the condition set forth in Paragraph 8.C. below on March 31 of each of the three consecutive calendar years following the date of the respective award; and
(2)    Up to 15,000 of the Stock Options to vest ratably and conditionally in thirds by no later than March 31 of each of the three consecutive calendar years following the date of the respective award, with the actual date of vesting, the applicable conditions (based on performance objectives disclosed to Executive no later than the end of the first quarter of the calendar year for which they apply), and Executive’s complete or partial satisfaction of the conditions (and, therefore, the number of Stock Options that vest based on performance) to be determined by the Compensation Committee in its sole and absolute discretion and subject to the condition set forth in Paragraph 8.C. below. 
C.    Except as provided in Paragraph 11.A. below, in order for any part of the LTIP awards set forth in this Paragraph 8 to vest, Executive must remain employed by Affinity through the scheduled date of vesting
9.Benefits.   During Executive’s employment with Affinity, Executive shall be entitled to participate in those employee benefit plans that Affinity may make generally available to its similarly situated employees provided that Executive otherwise meets the eligibility requirements of those plans.

10.Expenses.  Affinity will reimburse Executive for all reasonable business expenses that Executive incurs in connection with Executive’s performance of duties for Affinity upon submission of satisfactory documentation and in accordance with Affinity’s business expense reimbursement policy.  Affinity will pay Executive an additional $40,000 (grossed up for income tax liability), to compensate Executive for the relocation of his residence to Las Vegas, Nevada.  If Executive resigns or is terminated for Cause (as defined in Paragraph 11 below) within one year after Executive’s employment with Affinity begins, Executive will repay that amount promptly upon Affinity’s written request.  

11.Termination.   Either party may terminate Executive’s employment for any reason upon giving written notice to the other party.  Upon termination of Executive’s employment for any reason, Executive shall be entitled only to payment of Executive’s regular salary pro-rated through the termination date other than as set forth in Paragraph 11.A. below.  Immediately upon the termination of Executive’s employment, or upon Affinity’s request, Executive shall return to Affinity all of its and its affiliates’ property in Executive’s possession or under Executive’s control including, but not limited to, all Affinity documents, keys, credit cards, computers, cell phones, electronic devices, computer software, electronic information, Confidential and Proprietary Information (as defined in Paragraph 12 below) and all copies thereof.

A.In the event of termination of Executive’s employment by Affinity without Cause, and conditioned upon Executive’s execution of a full release of claims in a form reasonably acceptable to Affinity (the “Release”), Executive shall also be entitled to receive the following severance benefits and accelerated vesting of unvested LTIP awards in lieu of any compensation and benefits whatsoever:
(1)    continued payment of Executive’s base salary for the Severance Period (as defined below), such payments to commence beginning with the first payroll date following the expiration of eight days after Executive returns an executed copy of the Release to Affinity; 

(2)    continued participation in Affinity’s group medical plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1986 (“COBRA”) and conditioned upon Executive’s timely election of continuation of benefits, at Affinity’s expense until the earlier of (i) the last day of the month in which the salary continuation described in Subparagraph 11(A)(1) above expires and (ii) the date upon which Executive first becomes eligible for coverage provided by any other entity following termination of employment hereunder (irrespective of whether Executive actually enrolls in such coverage).  Executive shall provide Affinity with written notice of his eligibility for such other entity’s coverage no later than three days before Executive becomes eligible for such coverage; and
(3)    with respect to those Restricted Share or Stock Option awards that Executive has received under the LTIP as of Executive’s employment termination date in which the vesting conditions of the award are based solely upon a vesting date, and not upon any performance objectives or EBITDA target, that have not vested as of the employment termination date, will become immediately vested and exercisable by Executive as of the employment termination date.  
B.For the purposes of Paragraph 11.A. above, “Cause” means one or more of the following:
(1)  Executive’s breach of any material term of this Agreement;

(2)  Indictment of, or formal charge against, Executive for a felony or any other offense which involves an act of embezzlement, misappropriation of funds, or other conduct evidencing an act of moral turpitude, dishonesty or lack of fidelity; or, Executive’s admission of having engaged in the same;

(3)  Payment (or, by the operation solely of the effect of a deductible, the failure of payment) by a surety or insurer of a claim under a fidelity bond issued for the benefit of Affinity reimbursing Affinity for a loss due to the wrongful act, or wrongful omission to act, of the Executive;

(4)  Executive’s failure to obey the reasonable and lawful orders of an officer or the Board or a direct supervisor;

(5)  Executive’s misconduct or failure to discharge Executive’s duties commensurate with Executive’s title and function;

(6)  the denial, revocation or suspension of a license, qualification or certificate of suitability to the Executive by any governmental authority that holds regulatory, licensing or permit authority over gambling, gaming or casino activities (“Gaming Authority”) or the reasonable likelihood that the same will occur; or

(7)  any action or failure to act by Executive that Affinity or its affiliate reasonably believes, as a result of a communication or action by any Gaming Authority or on the basis of Affinity’s or its affiliate’s consultations with its legal counsel and/or other professional advisors, will likely cause any Gaming Authority to: (i) fail to license, qualify and/or approve Affinity or its affiliate to own and operate a gaming business; (ii) grant any such licensing, qualification and/or approval only upon terms and conditions that are unacceptable to Affinity or its affiliate; (iii) significantly delay any such licensing, qualification and/or approval process; or (iv) revoke or suspend any existing license.

C.For the purposes of Subparagraph 11.A.(1) above and Paragraph 14.B below, “Severance Period” means, for the first three years of this Agreement following the Effective Date, one year; for the fourth and fifth year following the Effective Date, nine months, and for the sixth year and thereafter, six months.

12.Non-Disclosure and Use of Confidential and Proprietary Information.  Executive acknowledges and agrees that Executive’s employment by Affinity will result in Executive’s exposure and access to confidential and proprietary information including, but not limited to, management, administration, and accounting systems, vendor and supplier costs, financial information, business and marketing strategies, databases, formulas, and personal information about Affinity, certain Shareholders of Affinity that employ or have contracted to appoint Board representatives (collectively, with their affiliates, “Board Shareholders”), and their respective owners, affiliates, principals, members, officers, directors, and employees (“Confidential and Proprietary Information”) which Executive did not have access to prior to Executive’s employment by Affinity and which information is of great value to Affinity, the Board Shareholders, and their respective owners, affiliates, principals, members, officers, directors, and employees.  Executive agrees that Executive shall not, other than on behalf of Affinity or the Board Shareholders, at any time during Executive’s employment with Affinity and thereafter, make available, divulge, disclose, or communicate in any manner whatsoever to anyone including, but not limited to, any person, firm, corporation, investor, member of the media, or entity, any Confidential and Proprietary Information, or use any Confidential and Proprietary Information for any purpose other than on behalf of Affinity or the Board Shareholders, unless previously 

authorized to do so in writing by Affinity's  Chief Executive Officer and/or the authorized representative of the Board Shareholder (“Authorized Board Representative”), as appropriate, required by law or court order, or the Confidential and Proprietary Information has become publicly available other than by reason of Executive’s breach of this Agreement or of another individual’s or entity’s violation of an obligation not to disclose such information.  Should Executive be required by law or court order to disclose any Confidential and Proprietary Information, Executive agrees to give Affinity and/or the Authorized Board Representative, as appropriate and permitted by law or court order, prompt notice so as to allow Affinity and/or the Board Shareholders to challenge such application of the law or court order, or otherwise to attempt to limit the scope of such disclosure.  This Paragraph 12 applies to all Confidential and Proprietary Information of Affinity, its affiliates, and the Board Shareholders, regardless of when such information is or was disclosed to Executive.

13.Patents, Copyrights, Trademarks, and Other Property Rights.  Any and all inventions, improvements, discoveries, formulas, technology, administration and accounting systems, processes, and computer software relating to Affinity’s or the Board Shareholders’ businesses (whether or not patentable), discovered, developed, or learned by Executive during Executive’s employment with Affinity (“Intellectual Property”) are the sole and absolute property of Affinity and/or a Board Shareholder and are “works made for hire” as that term is defined in the copyright laws of the United States.  Executive acknowledges and agrees that Affinity and/or a Board Shareholder is the sole and absolute owner of all patents, copyrights, trademarks, and other property rights to the Intellectual Property, Executive expressly disclaims any and all ownership rights to such Intellectual Property, and Executive will fully assist Affinity and/or the Board Shareholders to obtain the patents, copyrights, trademarks, or other property rights to all Intellectual Property.  Executive has been notified by Affinity and understands that the foregoing provisions of this Paragraph 13 do not apply to an invention for which no equipment, supplies, facilities, confidential, proprietary, or trade secret information of Affinity, its affiliates, or the Board Shareholders was used and which was developed entirely on Executive’s own time, unless the invention:  (a) relates to the business of Affinity, its affiliates, or the Board Shareholders or to their actual or demonstrably anticipated research and development, or (b) results from any work performed by Executive for Affinity, its affiliates, or the Board Shareholders.

14.Protective Covenants.  

A.During Executive’s employment and for a period of 12 months after the termination of Executive’s employment with Affinity, irrespective of the reason for termination, Executive agrees not to, directly or indirectly, other than on Affinity’s behalf:
(1)    Induce or assist in the inducement of any individual away from Affinity’s, its affiliates,’ the Board Shareholders’ or any of their respective portfolio companies’ employ or from the faithful discharge of such individual’s contractual and fiduciary obligations to serve Affinity’s, its affiliates,’ the Board Shareholders’ or their respective portfolio companies’  interests with undivided loyalty;
(2)    Induce or assist in the inducement of any individual or entity that provides products or services to Affinity, its affiliates, or the Board Shareholders or their respective portfolio companies to reduce any such products or services provided to, or to terminate their relationship with, Affinity, its affiliates, the Board Shareholders or their portfolio companies; and 
B.    During Executive’s employment and for a period after the termination of Executive’s employment with Affinity equal to the Separation Period, irrespective of the reason for termination, Executive agrees not to, directly or indirectly, other than on Affinity’s behalf, engage in any business activity, whether as an owner, partner, principal, employee, consultant, or otherwise, that involves hospitality, gaming, or casinos within a 150 mile radius of the location of any hospitality, casino, or gaming business operated by Affinity or any of its affiliates (“Restricted Area”), except that this Paragraph 14.B. does not preclude Executive from working for a hospitality, casino, or gaming business that is located in Las Vegas, Nevada and that abuts Las Vegas Boulevard between Russell Road and Sahara Avenue (“Excluded Area”), provided that such hospitality, casino, or gaming business is not affiliated in any way with any hospitality, casino, or gaming business that is located outside of the Excluded Area, but within the Restricted Area.  
For the avoidance of doubt, each of Paragraphs 14.A.-B. above are severable.
15.Non-Disparagement.    Executive agrees not to engage in any conduct, or make any statement in any form, that may disparage, defame, or otherwise diminish the reputation of Affinity, the Board Shareholders, and their respective affiliates, funds, products, services, owners, members, principals, investors, officers, directors, employees, or their respective families.    

16.Injunctive Relief.  Executive acknowledges and agrees that the covenants contained in Paragraphs 12-15 above are reasonable in scope and duration, do not unduly restrict Executive’s ability to engage in Executive’s 

livelihood, and are necessary to protect Affinity’s  and the Board Shareholders’ legitimate business interests.  Without limiting the rights of Affinity and/or the Board Shareholders to pursue any other legal and/or equitable remedy available to it for any breach by Executive of the covenants contained in Paragraphs 12-15 above, Executive acknowledges that a breach of those covenants would cause a loss to Affinity and/or the Board Shareholders for which they could not reasonably or adequately be compensated by damages in an action at law, that remedies other than injunctive relief could not fully compensate Affinity and/or the Board Shareholders for a breach of those covenants and that, accordingly, Affinity and/or the Board Shareholders shall be entitled to injunctive relief to prevent any breach or continuing breaches of Executive’s covenants set forth in Paragraphs 12-15 above, without the necessity of posting a bond.  It is the parties’ intention that if, in any action before any court empowered to enforce such covenants, any term, restriction, covenant, or promise is found to be unenforceable, then such term, restriction, covenant, or promise shall be deemed modified to the extent necessary to make it enforceable by such court.

17.Communication with Board Shareholders’ Investors and Prospective Investors.  Executive agrees not to knowingly contact any investor in a fund managed by any of the Board Shareholders or any prospective investor that is considering investing in a fund managed by any of the Board Shareholders.  Should any such investor or prospective investor contact Executive, Executive agrees to refrain from communicating with that investor or prospective investor and will immediately communicate to the appropriate Authorized Board Representative the circumstances of the investor or prospective investor contact.

18.Mandatory Mediation and Waiver of Jury Trial.  Executive agrees that prior to initiating any legal action, all disputes and claims of any nature that Executive may have against Affinity, its affiliates, or their owners, officers, members, directors, or supervisory employees including, but not limited to, all statutory, contractual, and common law claims (including all employment discrimination claims), will be submitted first to mandatory mediation in Las Vegas, Nevada, or at another mutually agreed-upon location, under the rules of Judicial Arbitration and Mediation Services (“JAMS”), or under such other rules as the parties may mutually agree.  All information regarding the dispute or claim or mediation proceedings, including any mediation settlement, shall not be disclosed by Executive or any mediator to any third party other than Executive’s advisors who first agree to maintain confidentiality of such information, without the written consent of Affinity’s Chief Executive Officer, such consent to not be unreasonably withheld, conditioned or delayed.  In the event that mediation does not resolve any dispute that Executive has with Affinity and Executive proceeds to file a complaint in court, EXECUTIVE HEREBY WAIVES ANY RIGHT TO A JURY TRIAL OF THAT DISPUTE.

19.Confidential Agreement.  The terms of this Agreement are confidential.  Accordingly, other than as set forth in Paragraph 20 below, Executive agrees not to disclose the terms of this Agreement to anyone other than to Executive’s attorney, accountant, or spouse without the express written consent of Affinity’s Chief Executive Officer or as otherwise required by law.  Should Executive disclose the terms of this Agreement to Executive’s attorney, accountant, or spouse, or to another third party expressly approved by Affinity’s Chief Executive Officer, Executive shall ensure that those individuals abide by the confidentiality terms of this Paragraph 19.

20.Notification Obligations.  Executive shall notify each individual, employer or other entity with which Executive forms a business relationship of Executive’s obligations under Paragraph 12 above.  For 12 months after Executive’s employment separation from Affinity, Executive also shall (a) promptly notify Affinity in writing identifying each individual, employer, or other entity with which Executive forms a business relationship and describing the nature of Executive’s duties, responsibilities, and relationship with that individual, employer, or entity; and (b) inform each individual, employer, or other entity with which Executive forms a business relationship of Executive’s obligations under Paragraph 14 above.
21.Cooperation.   Subsequent to the termination of Executive’s employment and upon Affinity’s request, Executive agrees to be reasonably available to provide assistance to Affinity with respect to any legal issue that arose during or involved the period in which Affinity employed Executive in which Executive has pertinent information.  Affinity will reimburse Executive for any reasonable expenses that Executive incurs in providing such assistance.  Should such assistance require a significant portion of Executive’s time, Affinity and Executive will confer to attempt to agree upon a reasonable rate of compensation that Affinity will pay for Executive’s time.

22.Severability.  In the event that any court having jurisdiction over this Agreement determines that one or more of the provisions contained in this Agreement shall be unenforceable in any respect, such provision shall be deemed limited and restricted to the portions that are enforceable.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision.

23.Assignment.  The services rendered by Executive to Affinity are unique and personal.  Accordingly, Executive may not assign any of Executive’s rights or delegate any of Executive’s duties or obligations under this Agreement.  

Affinity may, upon written notice to Executive, assign this Agreement to a purchaser or transferee of substantially all of the assets of Affinity.

24.Post-Employment Effectiveness.  Executive expressly acknowledges that Paragraphs 12-29 of this Agreement remain in effect after the termination of Executive’s employment with Affinity.

25.Notices.  All notices and other communications required or permitted under this Agreement shall be deemed to have been duly given and made if in writing and if served personally on the party for whom intended or by being mailed, postage prepaid, certified or registered mail with return receipt requested, or sent by a reputable overnight delivery service such as Federal Express or DHL that tracks its deliveries, to the address shown below for each such party or such other address as may be designated in writing hereafter by such party:

		
	(A)
	If to Affinity:        Affinity Gaming

3755 Breakthrough Way
Suite 300
Las Vegas, Nevada 89135
Attn:  General Counsel
                
         (B)    If to Executive:    The most recent home address that Affinity has on file for Executive. 
26.Waiver.  Affinity’s waiver of a breach by Executive of any provision of this Agreement or failure to enforce any such provision with respect to Executive shall not operate or be construed as a waiver of any subsequent breach by Executive of any such provision or of any other provision, or of Affinity’s right to enforce any such provision or any other provision with respect to Executive.  No act or omission of Affinity shall constitute a waiver of any of its rights hereunder except for a written waiver signed by Affinity’s Chief Executive Officer.

27.Third Party Beneficiaries.  Executive acknowledges and agrees that each Board Shareholder is an express third party beneficiary of Executive’s obligations hereunder and shall have full rights to enforce the terms of this Agreement against Executive.

28.Governing Law.  This Agreement shall in all respects be governed by the substantive laws of the State of Nevada without regard to its or any other state’s conflict of law rules.

29.Amendment.  The terms of this Agreement may be modified only by a writing signed by both Executive and Affinity’s Chief Executive Officer.

30.Entire Agreement.  This Agreement and the LTIP constitute the entire agreement and understanding of the parties hereto with respect to the matters described herein, and supersede any and all prior and/or contemporaneous agreements and understandings, oral or written, between the parties.

31.Counterparts.  This Agreement may be executed in counterparts, each of which taken together shall constitute one and the same instrument.  Facsimile or electronic transmission of an executed counterpart of this Agreement shall be deemed to constitute due and sufficient delivery of such counterpart, and such signatures shall be deemed original signatures for purposes of enforcement and construction of this Agreement.

EXECUTIVE AND AFFINITY EACH REPRESENT AND WARRANT THAT EACH HAS READ THIS AGREEMENT, EACH UNDERSTANDS ITS TERMS, AND EACH AGREES TO BE BOUND THEREBY.
EXECUTIVE                        AFFINITY GAMING

/s/ Walter Bogumil                    By: /s/ Michael Silberling            
Walter Bogumil                                 Michael Silberling
                      Chief Executive Officer

Dated: January 29, 2015                     Dated: January 29, 2015

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]